var title_f28_18_28960="Endoscopy - strongyloidiasis";
var content_f28_18_28960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopy - strongyloidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopic view of multiple 2 mm diameter nodules with surrounding erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Goh S-K, Chow P, Chung AY, et al. Strongyloides colitis in a patient with Cushing's syndrome. Gastrointest Endosc 2004; 59:738. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28960=[""].join("\n");
var outline_f28_18_28960=null;
var title_f28_18_28961="Esophageal adenocarcinoma";
var content_f28_18_28961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Esophageal adenocarcinoma at the gastroesophageal junction in a patient with Barrett's esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28961=[""].join("\n");
var outline_f28_18_28961=null;
var title_f28_18_28962="Flat warts forehead";
var content_f28_18_28962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flat warts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple flesh-colored flat-topped papules are present on the forehead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28962=[""].join("\n");
var outline_f28_18_28962=null;
var title_f28_18_28963="Rheumatoid nodule";
var content_f28_18_28963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Rheumatoid nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rheumatoid vasculitis tends to occur in patients with aggressive, erosive arthritis associated with rheumatoid nodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28963=[""].join("\n");
var outline_f28_18_28963=null;
var title_f28_18_28964="Dofetilide: Patient drug information";
var content_f28_18_28964=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dofetilide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     see \"Dofetilide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tikosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tikosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Start this drug in a setting where your heart will be watched nonstop. Go back to this setting if a higher dose is needed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dofetilide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703684",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low magnesium levels, low potassium levels, very bad kidney disease, or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698651",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much sweat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696552",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Never make up a missed dose. Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12391 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28964=[""].join("\n");
var outline_f28_18_28964=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162349\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029668\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029670\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029669\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029674\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029675\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029677\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029672\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029673\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029678\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029679\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=related_link\">",
"      Dofetilide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_18_28965="DNA replication";
var content_f28_18_28965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    DNA replication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28965=[""].join("\n");
var outline_f28_18_28965=null;
var title_f28_18_28966="Screening for chronic kidney disease";
var content_f28_18_28966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28966/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28966/contributors\">",
"     Gregorio T Obrador, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28966/contributors\">",
"     Brian JG Pereira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28966/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28966/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28966/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28966/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/18/28966/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10268505\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD) is a worldwide public health problem. In the United States, the prevalence of end-stage kidney disease (ESRD) is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/1\">",
"     1",
"    </a>",
"    ]. The rising prevalence of treated ESRD can be attributed to the increase in the number of patients who start renal replacement therapy (RRT) each year, and to the increased survival of patients with ESRD.",
"   </p>",
"   <p>",
"    Patients with ESRD consume a disproportionate share of health care resources [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, despite the magnitude of the resources committed to the treatment of ESRD, and the substantial improvements in the quality of dialysis therapy, these patients continue to experience significant mortality and morbidity and a reduced quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Underrecognition of earlier stages of CKD and of risk factors for CKD, may partially explain the rising prevalence of treated ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/1\">",
"     1",
"    </a>",
"    ]. Increasing evidence accumulated in the past decades indicates that earlier stages of CKD can be detected through laboratory testing, and that therapeutic interventions implemented early in the course of CKD are effective in slowing or preventing the progression toward ESRD and its associated complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews recommendations for screening patients for CKD. Overviews of the epidemiology and management of CKD and its complications are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=see_link\">",
"     \"Epidemiology of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10268965\">",
"    <span class=\"h1\">",
"     UNDERRECOGNITION OF CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some evidence suggests that CKD is underrecognized. Based upon findings from the National Health and Nutrition Examination Survey (NHANES), for example, awareness of kidney disease in the United States population is low, particularly among certain patient subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/8\">",
"     8",
"    </a>",
"    ]. Awareness of kidney disease was reported in 40.5, 29.3, 22, and 44.5 percent of patients with stage 1, 2, 3, and 4 disease, respectively. Non-Hispanic blacks, men, and those with hypertension were less likely to know that they had some degree of kidney disease.",
"   </p>",
"   <p>",
"    A similar lack of awareness was noted in a second study based on the NHANES data [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/9\">",
"     9",
"    </a>",
"    ]. In this study, women were much less likely to be aware they had decreased renal function. This was thought to be due to the misinterpretation of clinicians of a \"normal\" serum creatinine concentration.",
"   </p>",
"   <p>",
"    This lack of awareness extends to physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 6895 outpatients who had at least two GFR estimates of less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2, only 27 percent carried a diagnosis of CKD anywhere on the chart [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second retrospective study, 587 Medicare patients younger than 75 years were admitted with a primary diagnosis of diabetes mellitus or hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/10\">",
"       10",
"      </a>",
"      ]. Patients with a known history of CKD of any cause, including diabetes and hypertension, were excluded. During the hospitalization, only 0.6 and 1.6 percent of patients with hypertension and diabetes, respectively, were investigated for microalbuminuria. Among patients with diabetes and hypertension, a urinalysis was performed in only 68 and 58 percent, respectively, and serum creatinine was obtained in only 91 and 97 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of these studies suggest that even among individuals at high risk, testing for early detection of kidney disease is not universal.",
"   </p>",
"   <p>",
"    Over the last several years, however, implementation of the 2002",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines may have increased awareness of CKD. In the National Hospital Discharge Survey, a rapid increase in admissions related to kidney disease appeared to begin in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/13\">",
"     13",
"    </a>",
"    ]. The age-adjusted hospitalization rates (per 10,000 population) for kidney disease were 39.0, 42.7, 46.1, and 54.6 for the years 2002, 2003, 2004, and 2005, respectively, versus a stable rate between 32 and 35 for the years between 1991 and 2000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10268972\">",
"    <span class=\"h1\">",
"     SCREENING FOR CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines for CKD, which have been reviewed and endorsed by the 2006 Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference, recommend that all individuals should be assessed as part of routine health examinations to determine whether they are at increased risk for developing CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are at risk for developing CKD should be screened with both a urine test for proteinuria and a blood test for creatinine to estimate GFR. Patients who are at risk for glomerulonephritis should be screened for hematuria with a urinalysis. (See",
"    <a class=\"local\" href=\"#H2666200\">",
"     'Methods of screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24215381\">",
"    <span class=\"h2\">",
"     Risk factors for CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of diabetes, hypertension or cardiovascular disease confers the highest risk for developing CKD and individuals who have such a history should be screened [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there are multiple putative risk factors, such as obesity, that may be associated with CKD. A post-hoc analysis of the Add Health Wave III cohort of young adults revealed an association between a body mass index over 35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    and proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/15\">",
"     15",
"    </a>",
"    ]. The relationship between body weight and glomerular filtration rate is less clear. The waist-to-hip ratio, but not the body mass index, has been independently associated with the incidence of stage 3 CKD in older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition, weight gain, even within the normal range of body mass index, may increase the risk of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/18\">",
"     18",
"    </a>",
"    ]. It is not clear whether obese individuals should be screened for CKD. A prospective study of the relationship between obesity and proteinuria as an early marker of CKD is necessary.",
"   </p>",
"   <p>",
"    In general, the presence of the following risk factors for CKD should provoke formal testing for CKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of diabetes, cardiovascular disease, hypertension, hyperlipidemia, obesity, metabolic syndrome, smoking, HIV or hepatitis C virus infection, and malignancy",
"     </li>",
"     <li>",
"      Family history of kidney disease",
"     </li>",
"     <li>",
"      Treatment with potentially nephrotoxic drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference suggests screening all patients over age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/14\">",
"     14",
"    </a>",
"    ]. This approach has not received widespread acceptance and more data are needed before such screening is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2666200\">",
"    <span class=\"h3\">",
"     Methods of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have risk factors for CKD should be screened with both a urine test for albumin in a first morning or a random \"spot\" urine sample and a blood test for creatinine to estimate GFR. The preferred screening strategy for albuminuria is measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link&amp;anchor=H9#H9\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Quantitative measurement'",
"    </a>",
"    .) Screening for hematuria with a urinalysis should be done in selected populations that are at increased risk for glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated GFR, and the threshold of less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 to define CKD, has limitations as a screening and diagnostic tool, particularly among elderly individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20658511#H20658511\">",
"     \"Assessment of kidney function\", section on 'Change in GFR with aging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the presence of particular risk factors, additional testing such as renal ultrasonography may be required, for example in patients with a family history of polycystic kidney disease. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Once the diagnosis is established and the cause",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potentially reversible factors are identified and treated, CKD should be staged according to the classification proposed by the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    Clinical Practice Guidelines for Evaluation, Classification and Stratification of CKD and subsequently revised. (",
"    <a class=\"graphic graphic_table graphicRef70597 \" href=\"UTD.htm?13/47/14076\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This classification is based on laboratory evaluation of the severity of kidney disease, association of level of kidney function with complications, and stratification of risks for loss of kidney function and development of cardiovascular disease (CVD). The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    classification also includes an action plan for each stage of the disease.",
"   </p>",
"   <p>",
"    The frequency of testing for CKD in high risk groups has not been rigorously studied and recommendations are opinion based. The National Kidney Disease Education Program (NKDEP) of the National Institutes of Health (NIH) recommends yearly testing among diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Screening for increased urinary albumin excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertensive patients should be tested at diagnosis; upon initiation of therapy, and every three years thereafter. Individuals with a family history of CKD should be tested every three years. Individuals with other risk factors may be tested less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2666173\">",
"    <span class=\"h2\">",
"     Screening the general population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the relatively low prevalence of CKD in the United States, massive screening in the general population is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such screening, however, would almost certainly detect individuals who have no identified risk factors but are at risk for progression to ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study, in which 40,854 individuals in the Netherlands aged 28 to 75 years were screened for increased urinary albumin excretion, almost half of the individuals who ultimately required renal replacement therapy (RRT) had microalbuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/23\">",
"     23",
"    </a>",
"    ]. Screening only high-risk individuals identified 55 percent of those with microalbuminuria, and 87 percent of those who progressed to RRT. Because 40 to 50 percent of individuals with microalbuminuria did not have risk factors for CKD, the authors advocated screening the general population rather than targeting screening to those at increased risk.",
"   </p>",
"   <p>",
"    However, among 25,597 PREVEND participants who did not have any risk factors for CKD there were only six cases of end-stage renal disease. As a result, a very large number of individuals would need to be tested and treated in order to possibly prevent one case of end stage renal disease. In addition, although the relatively low cost of testing urine microalbuminuria favors massive screening, the total costs of the of the screening program also include the time and effort to collect specimens, the cost of confirmatory tests for treatment of a positive test, and the costs of monitoring and treatment of complications associated with interventions.",
"   </p>",
"   <p>",
"    Finally, there are no data to support that angiotensin-converting enzyme inhibitors or angiotensin-receptor antagonists decrease the risk of end stage renal disease or a clinically significant loss of GFR among individuals who have microalbuminuria but no other risk factors.",
"   </p>",
"   <p>",
"    In a cost-effectiveness analysis performed by the Centers for Disease Control (CDC), CKD screening with microalbuminuria was cost effective only for individuals with diabetes or hypertension or aged older than 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United State Preventive Services Task Force has concluded that evidence is insufficient to assess benefits and screening of asymptomatic adults (excluding testing for and monitoring as part of management of chronic diseases such as diabetes or hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10268979\">",
"    <span class=\"h2\">",
"     Kidney Early Evaluation Program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NKF-sponsored Kidney Early Evaluation Program (KEEP) is a screening program targeted at individuals 18 years of age or older at high risk for developing CKD because they have diabetes, hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    first order relatives with those conditions or kidney disease. KEEP offers free blood and urine testing, on-site consultation by a physician, referrals, and additional follow-up for those whose test results are outside normal ranges [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Data collected include age, family history, height, weight, blood pressure, microalbuminuria, pyuria, and hematuria, plasma glucose, and serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/29\">",
"     29",
"    </a>",
"    ]. Among 89,622 KEEP participants, the overall CKD prevalence was 26 percent, of which 17 percent had stage 3, and 1 percent stages 4 or 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has also launched the National Kidney Disease Education Program (NKDEP). This program aims at increasing awareness of the risk for CKD especially among providers for high-risk groups and to develop straightforward management steps for the primary care physicians based upon the formal guidelines being developed by the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10268986\">",
"    <span class=\"h2\">",
"     Laboratory database screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have reported the prevalence of CKD using available laboratory test results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Based upon the recommendations by the NKF that GFR should be estimated to determine the presence and severity of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/1\">",
"     1",
"    </a>",
"    ], automated reporting of estimated GFR whenever a plasma creatinine concentration is ordered should probably be implemented in clinical sites [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This may be a fairly cost-effective method of identifying patients with CKD. Some areas within the United States have passed legislation that mandates reporting of the estimated GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/37\">",
"     37",
"    </a>",
"    ]. However, this issue continues to be debated because of the controversy about the definition of CKD for older age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28966/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10269534\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic kidney disease (CKD) may be underrecognized, which may be contributing to the rising prevalence of end-stage renal disease (ESRD). Therapeutic interventions implemented early in the course of CKD are effective in slowing or preventing the progression toward ESRD and its associated complications. (See",
"      <a class=\"local\" href=\"#H10268505\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10268965\">",
"       'Underrecognition of CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       NKF-K/DOQI",
"      </span>",
"      guidelines for CKD, which have been reviewed and endorsed by the 2006 Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference, recommend that all individuals should be assessed as part of routine health examinations to determine whether they are at increased risk for developing CKD. Important risk factors for CKD include diabetes, hypertension and cardiovascular disease; other risk factors to be considered include a positive family history for kidney disease cardiovascular risk factors, such as hyperlipidemia, obesity, metabolic syndrome, smoking; HIV or hepatitis C virus infection, and malignancy. (See",
"      <a class=\"local\" href=\"#H10268972\">",
"       'Screening for CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all patients who have risk factors for CKD should be screened with both a urine test for albumin in a first morning or a random \"spot\" urine sample and a blood test for creatinine to estimate GFR. Additional testing such as renal ultrasonography may be required, for example in patients with a family history of polycystic kidney disease. (See",
"      <a class=\"local\" href=\"#H2666200\">",
"       'Methods of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of testing for CKD in high risk groups has not been rigorously studied and recommendations are opinion based. We suggest that hypertensive patients should be tested at diagnosis; upon initiation of therapy, and every three years thereafter. Individuals with a family history of CKD should be tested every three years. The screening of diabetic patients is discussed elsewhere. (See",
"      <a class=\"local\" href=\"#H10268972\">",
"       'Screening for CKD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of medical care in adults with diabetes mellitus\", section on 'Screening for increased urinary albumin excretion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of the relatively low prevalence of CKD in the United States, massive screening in the general population is not recommended. (See",
"      <a class=\"local\" href=\"#H2666173\">",
"       'Screening the general population'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     United States Renal Data System 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2000 Annual Data Report.: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/4\">",
"      McClellan WM, Anson C, Birkeli K, Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 1991; 44:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/5\">",
"      DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997; 30:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/6\">",
"      Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/7\">",
"      Pereira BJ. Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int 2000; 57:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/8\">",
"      Nickolas TL, Frisch GD, Opotowsky AR, et al. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 2004; 44:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/9\">",
"      Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/10\">",
"      McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis 1997; 29:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/11\">",
"      Ryan TP, Sloand JA, Winters PC, et al. Chronic kidney disease prevalence and rate of diagnosis. Am J Med 2007; 120:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/12\">",
"      Kissmeyer L, Kong C, Cohen J, et al. Community nephrology: audit of screening for renal insufficiency in a high risk population. Nephrol Dial Transplant 1999; 14:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Hospitalization discharge diagnoses for kidney disease--United States, 1980-2005. MMWR Morb Mortal Wkly Rep 2008; 57:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/14\">",
"      Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/15\">",
"      Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol 2007; 2:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/16\">",
"      Elsayed EF, Sarnak MJ, Tighiouart H, et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 2008; 52:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/17\">",
"      Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/18\">",
"      Ryu S, Chang Y, Woo HY, et al. Changes in body weight predict CKD in healthy men. J Am Soc Nephrol 2008; 19:1798.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nkdep.nih.gov/professionals/chronic_kidney_disease.htm#diagnosis.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/20\">",
"      Fried L. Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 2009; 20:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/21\">",
"      de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol 2006; 17:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/22\">",
"      Gansevoort RT, Bakker SJ, de Jong PE. Early detection of progressive chronic kidney disease: is it feasible? J Am Soc Nephrol 2006; 17:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/23\">",
"      van der Velde M, Halbesma N, de Charro FT, et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009; 20:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/24\">",
"      Imai E, Yamagata K, Iseki K, et al. Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol 2007; 2:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/25\">",
"      Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 2010; 55:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/26\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/27\">",
"      Annual Data Report of the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2003; 42; 5(Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/28\">",
"      Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2003; 42:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/29\">",
"      National Kidney Foundation Kidney Early Evaluation Program (KEEP), KEEP 2006 data report. Am J Kidney Dis 2007; 49(Suppl 3):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/30\">",
"      National Kidney Foundation. Kidney Early Evaluation Program. Annual Data Report. Am J Kidney Dis 2009; 53 (Suppl 4): S1-S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/31\">",
"      Narva A. Screening is part of kidney disease education. Clin J Am Soc Nephrol 2007; 2:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/32\">",
"      Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/33\">",
"      Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 2001; 37:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/34\">",
"      Garg AX, Mamdani M, Juurlink DN, et al. Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance. J Am Soc Nephrol 2005; 16:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/35\">",
"      Thorp ML, Eastman L. Potential application of the National Kidney Foundation's chronic kidney disease guidelines in a managed care setting. Am J Manag Care 2004; 10:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/36\">",
"      Yeoh HH, Rasgon S, Rutkowski M, et al. Management of patients with chronic kidney disease at Kaiser Permanente. Nephrol News Issues 2003; 17:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/37\">",
"      McDonough DP. New Jersey's experience: mandatory estimated glomerular filtration rate reporting. Clin J Am Soc Nephrol 2007; 2:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/38\">",
"      Melamed ML, Bauer C, Hostetter TH. eGFR: is it ready for early identification of CKD? Clin J Am Soc Nephrol 2008; 3:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28966/abstract/39\">",
"      Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol 2008; 3:1563.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15768 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28966=[""].join("\n");
var outline_f28_18_28966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10269534\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10268505\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10268965\">",
"      UNDERRECOGNITION OF CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10268972\">",
"      SCREENING FOR CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24215381\">",
"      Risk factors for CKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2666200\">",
"      - Methods of screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2666173\">",
"      Screening the general population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10268979\">",
"      Kidney Early Evaluation Program",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10268986\">",
"      Laboratory database screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10269534\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/15768\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/15768|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/47/14076\" title=\"table 1\">",
"      Revised CKD classification based upon GFR and albuminuria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_18_28967="Endoscopic ultrasound in rectal cancer";
var content_f28_18_28967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic ultrasound in rectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28967/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28967/contributors\">",
"     Gavin C Harewood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28967/contributors\">",
"     Maurits J Wiersema, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28967/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28967/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28967/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28967/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/18/28967/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate staging of rectal cancer is essential for selecting patients who can undergo sphincter-preserving surgery and identifying those who could benefit from neoadjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical staging is usually accomplished using a combination of physical examination and CT scanning. Other imaging modalities such as magnetic resonance imaging, transrectal and transvaginal ultrasound using rigid instruments, and transrectal endoscopic ultrasound are also frequently used, although their roles are still being determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=see_link&amp;anchor=H5#H5\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'Imaging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will summarize experience with endoscopic ultrasound. Discussions on the diagnosis and management of rectal cancer (including other staging methods) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transrectal endoscopic ultrasound (EUS) is performed with the patient in the left lateral decubitus position. However, optimal tumor visualization may require repositioning the patient to place the region of interest in the dependent portion of the rectum. This is particularly important when assessing the primary tumor (T) stage of early superficial lesions because the rectum is filled with water, and minimal compression by the balloon is desired to achieve acoustic coupling.",
"   </p>",
"   <p>",
"    A radial scanning echoendoscope is inserted approximately 30 cm to assess for iliac adenopathy. The wall and periluminal structures are carefully inspected while slowly withdrawing the echoendoscope. If necessary, the linear scanning echoendoscope is also inserted for fine needle aspiration (FNA) sampling of suspicious extramural lesions",
"    <span class=\"nowrap\">",
"     (mass/adenopathy)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59895 \" href=\"UTD.htm?15/11/15539\">",
"     image 1",
"    </a>",
"    ). The American Society for Gastrointestinal Endoscopy guidelines regarding endoscopic prophylaxis for gastrointestinal procedures do not make a recommendation with regard to antibiotic prophylaxis for EUS-FNA of solid lesions in the lower gastrointestinal tract. Our practice is to give prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    prior to the FNA (500 mg orally 30 to 60 minutes prior to the procedure or 400 mg IV 30 minutes prior). Oral ciprofloxacin (250 to 500 mg twice daily) is then given for 48 hours after the procedure. However, not all endoscopists routinely use antibiotics in this setting. Conscious sedation is not mandatory but may be helpful when EUS-guided FNA is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rectal ultrasound can be performed with rigid instruments, our preference is to use the flexible fiberoptic echoendoscope to facilitate traversal of stenotic tumors and permit assessment of lymph nodes in the left iliac region. The major limitations of rigid instruments are their restricted ability to image and perform FNA in the proximal rectum and evaluate for lymphadenopathy in the region of the left iliac vessels. Whether this impacts adversely on staging accuracy remains to be seen and a prospective, randomized trial would be required to answer this question. The rigid probes are substantially less expensive than the flexible dedicated echoendoscopes (approximately one-third the cost); however, they do not have the spectrum of capabilities (imaging of the upper intestinal tract).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067157148\">",
"    <span class=\"h2\">",
"     T stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies comparing the accuracy of transrectal EUS (TEUS) to CT and MRI suggest that TEUS is superior for T staging of rectal cancer (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). The accuracy of TEUS reported in many studies ranges from 80 to 95 percent, compared with 65 to 75 percent for CT, and 75 to 85 percent for MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. A meta-analysis of 42 studies estimated the following sensitivities and specificities of EUS for determining T-stages: T1 (88 and 98 percent), T2 (81 and 96 percent), T3 (96 and 91 percent), and T4 (95 and 98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/8\">",
"     8",
"    </a>",
"    ]. A decision-analysis suggested that the most cost-effective strategy for evaluation of nonmetastatic proximal rectal cancer was the combination of abdominal CT plus TEUS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/9\">",
"     9",
"    </a>",
"    ]. The main benefit of TEUS was in improving T staging.",
"   </p>",
"   <p>",
"    The improved accuracy of T staging may translate into changes in management. This was illustrated in a study at our institution in which we compared the impact of pelvic CT and TEUS in a cohort of 80 patients with newly diagnosed, nonmetastatic rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/10\">",
"     10",
"    </a>",
"    ]. The addition of TEUS to the work-up of these patients affected a change in management (preoperative or neoadjuvant therapy) in almost one-third of patients, mostly because CT tended to underestimate the T stage. In patients for whom neoadjuvant therapy would typically be considered, TEUS understaged the cancer less often than did CT (15 versus 39 percent) using surgical pathology as the gold standard. Moreover, TEUS correctly identified 62 percent of patients with",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    disease that were missed by CT, resulting in the administration of neoadjuvant therapy to patients who would not otherwise have been offered this treatment based upon staging information from CT alone.",
"   </p>",
"   <p>",
"    One major concern with the use of TEUS to select patients for neoadjuvant strategies is the risk of overtreating those with early stage disease (ie,",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    N0 tumors) who have been erroneously overstaged (",
"    <a class=\"graphic graphic_picture graphicRef63095 \" href=\"UTD.htm?3/17/3349\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50261 \" href=\"UTD.htm?36/8/36993\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65054 \" href=\"UTD.htm?23/22/23905\">",
"     image 3",
"    </a>",
"    ). However, in our series, there were no false positives in our T staging assessment (ie, no patients were erroneously overstaged as",
"    <span class=\"nowrap\">",
"     T3/4)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar findings have been described by others [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/1-7,11-31\">",
"     1-7,11-31",
"    </a>",
"    ]. Likewise, CT scanning rarely overestimated T stage, only misinterpreting one",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    patient with more advanced T stage disease, suggesting that treatment decisions based upon T stage as determined by either of these modalities will rarely expose patients with early stage disease to the risk of overtreatment.",
"   </p>",
"   <p>",
"    However, at least one large study suggests that the accuracy of EUS for T staging when performed in the course of routine clinical care (as opposed to in the setting of a study) may not be as high as that seen in studies performed in centers with expertise in TEUS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/32\">",
"     32",
"    </a>",
"    ]. The study examined 7096 patients who underwent both TEUS and surgery but who had not received neoadjuvant chemoradiotherapy. Endoscopic staging correlated with pathologic staging in only 65 percent of cases. Understaging occurred in 18 percent of TEUS examinations, and overstaging occurred in 17 percent. TEUS was most accurate in hospitals that performed &gt;30 TEUS per year (73 percent), and it was lowest for hospitals that performed 10 or fewer (63 percent). The sensitivity and specificity also varied by depth of tumor invasion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T1 (by ultrasound): sensitivity 58 percent, specificity 96 percent",
"     </li>",
"     <li>",
"      T2 (by ultrasound): sensitivity 64 percent, specificity 74 percent",
"     </li>",
"     <li>",
"      T3 (by ultrasound): sensitivity 71 percent, specificity 76 percent",
"     </li>",
"     <li>",
"      T4 (by ultrasound): sensitivity 27 percent, specificity 99 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When local expertise is available, we suggest the routine use of preoperative TEUS in the evaluation of potentially resectable rectal cancer because of its previously demonstrated excellent T staging accuracy when performed by an experienced endosonographer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     N stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single imaging modality is sufficiently accurate to allow for confident determination of the presence or absence of metastatic nodal involvement. A number of comparative studies have suggested that the accuracy of TEUS (approximately 70 to 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/1,2,4,7,21-23,25-31,33\">",
"     1,2,4,7,21-23,25-31,33",
"    </a>",
"    ] is similar to CT (55 to 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and MRI (60 to 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A meta-analysis of 35 studies estimated that the pooled sensitivity and specificity for TEUS in diagnosing nodal involvement by rectal cancers were 73 (95% CI 71 to 76 percent) and 76 percent (95% CI 74 to 78 percent), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Fine needle aspiration biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience, EUS-guided FNA does not appear to improve the staging of rectal cancer in most patients. This was underscored in our series in which we attempted to define the role of TEUS-guided FNA of perirectal lymph nodes in the preoperative assessment of a cohort of 80 patients with newly diagnosed, nonmetastatic rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/10\">",
"     10",
"    </a>",
"    ]. The overall accuracy of N staging was similar (about 80 percent) for CT, TEUS, and TEUS FNA.",
"   </p>",
"   <p>",
"    However, different conclusions were reached in another preliminary report that included 51 patients with rectal cancer undergoing EUS, of whom 15 had EUS-guided FNA of perirectal nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/35\">",
"     35",
"    </a>",
"    ]. Nodal disease was suspected by EUS in only 4 of the 12 patients (33 percent) with pathologically node positive (pN+) tumors at resection; the overall staging accuracy for nodal status was 70 percent. In contrast, EUS-guided FNA correctly identified positive nodes preoperatively in six of six pN+ patients. The use of EUS-guided FNA overall correctly predicted nodal status in 13 of 15 patients (87 percent). Further studies are still required to evaluate the utility of EUS FNA in this setting.",
"   </p>",
"   <p>",
"    One reason why FNA may not add significantly to TEUS alone is that perirectal lymph nodes are typically too small to be visualized by TEUS unless they contain metastatic disease. Thus, biopsy would not be expected to improve sensitivity when compared to visual criteria alone (eg, size, homogeneity, contour). This is in contrast to the demonstrated benefit of TEUS-guided FNA that has been observed when evaluating regional lymph nodes in other parts of the digestive tract [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/36-44\">",
"     36-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .) We currently perform FNA only in patients who appear to have early T stage disease but who also have evident peri-iliac lymphadenopathy, and in patients suspected of having recurrent disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Recurrent rectal cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Importantly, the incorporation of EUS FNA into the evaluation of patients with rectal cancer not only achieves superior staging accuracy to alternative imaging modalities, but may also improve patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/45\">",
"     45",
"    </a>",
"    ]. A study comparing patients with rectal cancer who underwent staging with EUS FNA with a similarly matched patient group who did not found that EUS FNA was associated with reduced tumor recurrence risk (hazard ratio, 0.72, 95% CI 0.52 to 0.97). EUS FNA likely achieved this effect through accurate staging, which facilitated optimal selection of patients with locally advanced disease who benefited maximally from preoperative neoadjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067157171\">",
"    <span class=\"h2\">",
"     Circumferential resection margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with anterior tumors, EUS can assess the extent of tumor involvement of the mesorectal fascia (MRF, the lateral margin) by predicting the distance of the tumor to the circumferential resection plane after rectal cancer surgery, called the circumferential resection margin (CRM). For posterior or posterolateral tumors, the distance to the CRM cannot be estimated using EUS because neighboring structures that allow assessment of the CRM are lacking. In such cases, the distance to the CRM can be estimated using MRI.",
"   </p>",
"   <p>",
"    The distance from the tumor to the CRM has important prognostic implications and may influence which patients are offered neoadjuvant chemoradiotherapy. A \"positive\" CRM, defined variably as a tumor that invades or is in close proximity to the MRF, is the most important risk factor for local recurrence after rectal cancer surgery. If the MRF is involved or if the tumor extends to a point that is within 1 to 2 mm of the MRF, there is a clear risk that the CRM will be involved if only a total mesorectal excision is performed. As a result, these patients are usually approached with initial chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H2#H2\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Indications for neoadjuvant treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=see_link&amp;anchor=H10#H10\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'MRI scan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study examined 152 patients whose preoperative staging suggested either a lymph node-positive T2 tumor or a T3 tumor regardless of lymph node involvement; no patient received neoadjuvant chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/46\">",
"     46",
"    </a>",
"    ]. The estimated CRM was determined using EUS alone (49 percent of patients), EUS plus MRI (41 percent), or MRI alone (10 percent of patients). The CRM was considered \"threatened\" if the tumor was within 2 mm, and \"non-threatened\" if it was more than 2 mm from the CRM based upon EUS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI. If the preoperative staging categorized the CRM as potentially free, then the histologic margin was clear in 92 percent of cases. If the CRM was not assessed or was defined as threatened, it was involved in 33 and 44 percent of patients, respectively.",
"   </p>",
"   <p>",
"    Upon histologic review of the resected specimen, the distance from the tumor to the CRM was an important predictor of local recurrence, disease-free survival, and cancer-specific survival on multivariable analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=see_link&amp;anchor=H623938#H623938\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'TRUS versus MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LEARNING CURVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general concern related to EUS is whether the published results (derived from centers with the most experience with EUS) can be generalized since a learning curve has been widely recognized. Although a learning curve clearly exists in mastering this transrectal EUS, the technique is relatively straightforward compared to EUS in other areas (particularly the pancreas and mediastinum). These points were illustrated in a report in which staging accuracy improved from 58 percent for the initial 12 studies to 88 percent for the remaining 24 examinations (a rapid rate of improvement) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RECURRENT RECTAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local recurrences often develop extraluminally, making early detection difficult during standard endoscopic follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .) In this setting, CT scanning may not be capable of distinguishing recurrence from postoperative change due to fibrosis or inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/49\">",
"     49",
"    </a>",
"    ]. Furthermore, images can be obscured by artifacts from surgically placed metal clips. TEUS combines the diagnostic potential of video endoscopy (endoluminal tumor detection) with CT (extramural tumor detection) and has proven to be a sensitive and specific method for detecting local recurrence. However, its performance is somewhat diminished in the posttreatment setting because of postoperative or post-radiation inflammatory soft tissue changes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. These changes obscure the mucosal layers of the rectum, making ultrasonographic images difficult to interpret.",
"   </p>",
"   <p>",
"    Despite these limitations, at least two prospective studies have demonstrated superior performance characteristics of TEUS when compared with pelvic CT for detection of local recurrence of rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/50,55\">",
"     50,55",
"    </a>",
"    ]. The sensitivity of TEUS for detecting recurrence was higher (100 percent) in both studies compared to CT (82 to 85 percent). However, a major limitation of EUS in this setting is a loss of specificity due to misinterpretation of mucosal inflammation as recurrent tumor (89 versus 93 percent for CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/55\">",
"     55",
"    </a>",
"    ]. On the other hand, unlike CT, EUS FNA permits histological confirmation of tumor recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fine needle aspiration biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to initial staging, the accuracy of TEUS for recurrent disease may be improved with the addition of FNA. In a study of 312 patients, for example, FNA significantly improved accuracy compared to TEUS alone (92 versus 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/56\">",
"     56",
"    </a>",
"    ]. The superior accuracy was primarily reflected in better specificity (93 versus 57 percent for CT).",
"   </p>",
"   <p>",
"    Similar conclusions were reached in another series of 116 patients with biopsy-proven tumor recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/57\">",
"     57",
"    </a>",
"    ]. Accuracy for detection of recurrence was 79 percent with TEUS alone but rose to 100 percent when TEUS-guided FNA was used to differentiate between malignant and benign pararectal lesions. The biggest advantage of TEUS FNA in this population was the ability to detect very small pararectal recurrences (the smallest tumor being 3 mm) allowing for potentially curative resection. Thirty-one of 116 patients (27 percent) with local recurrence detected by TEUS FNA were suitable candidates for reexploration, of whom only 25 would have been identified by EUS alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Follow-up after resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although TEUS, and particularly TEUS FNA, offers a benefit compared with conventional radiographic studies in detecting local recurrence, there is no consensus as to the optimal frequency or timing of follow-up study in these patients. Performing a baseline posttreatment TEUS three months following surgery may reduce the limitation of misinterpreting postoperative changes since by this time, most treatment-related changes have stabilized [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/55\">",
"     55",
"    </a>",
"    ]. In the study mentioned above, TEUS was performed at three-month intervals until two years and subsequently at six-month intervals until three years post surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, there is no general agreement as to which patients should be selected for close follow-up with TEUS. A reasonable approach would be to perform the most aggressive surveillance in patients who had locally advanced tumors, and those in whom local (ie, transanal) excision was performed, since such patients have the highest risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28967/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H1#H1\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the routine use of preoperative transrectal endoscopic ultrasound (TEUS) in the evaluation of rectal cancer because of its excellent T staging accuracy provided that a competent endosonographer is available (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with computed tomography, TEUS frequently upstages patients, making them eligible for neoadjuvant treatment. Fine-needle aspiration (FNA) should be reserved for patients who appear to have early T stage disease but with suspicious peri-iliac lymphadenopathy. The accurate staging ability of TEUS and TEUS FNA with appropriate preoperative chemoradiation in those patients with transmural disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphadenopathy translates into improved outcomes in terms of reduced recurrence rates, decreased frequency of colostomy and reduction in treatment complications. However, no improvement in survival is apparent. The role of EUS in patients with recurrent rectal cancer and as follow-up after resection remains unsettled. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recurrent rectal cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/1\">",
"      Hildebrandt U, Klein T, Feifel G, et al. Endosonography of pararectal lymph nodes. In vitro and in vivo evaluation. Dis Colon Rectum 1990; 33:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/2\">",
"      Tio TL, Coene PP, van Delden OM, Tytgat GN. Colorectal carcinoma: preoperative TNM classification with endosonography. Radiology 1991; 179:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/3\">",
"      Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. Int J Colorectal Dis 2000; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/4\">",
"      Thaler W, Watzka S, Martin F, et al. Preoperative staging of rectal cancer by endoluminal ultrasound vs. magnetic resonance imaging. Preliminary results of a prospective, comparative study. Dis Colon Rectum 1994; 37:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/5\">",
"      Meyenberger C, Huch B&ouml;ni RA, Bertschinger P, et al. Endoscopic ultrasound and endorectal magnetic resonance imaging: a prospective, comparative study for preoperative staging and follow-up of rectal cancer. Endoscopy 1995; 27:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/6\">",
"      Guinet C, Buy JN, Ghossain MA, et al. Comparison of magnetic resonance imaging and computed tomography in the preoperative staging of rectal cancer. Arch Surg 1990; 125:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/7\">",
"      Rifkin MD, Ehrlich SM, Marks G. Staging of rectal carcinoma: prospective comparison of endorectal US and CT. Radiology 1989; 170:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/8\">",
"      Puli SR, Bechtold ML, Reddy JB, et al. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann Surg Oncol 2009; 16:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/9\">",
"      Harewood GC, Wiersema MJ. Cost-effectiveness of endoscopic ultrasonography in the evaluation of proximal rectal cancer. Am J Gastroenterol 2002; 97:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/10\">",
"      Harewood GC, Wiersema MJ, Nelson H, et al. A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer. Gastroenterology 2002; 123:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/11\">",
"      Saitoh N, Okui K, Sarashina H, et al. Evaluation of echographic diagnosis of rectal cancer using intrarectal ultrasonic examination. Dis Colon Rectum 1986; 29:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/12\">",
"      Accarpio G, Scopinaro G, Claudiani F, et al. Experience with local rectal cancer excision in light of two recent preoperative diagnostic methods. Dis Colon Rectum 1987; 30:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/13\">",
"      Holdsworth PJ, Johnston D, Chalmers AG, et al. Endoluminal ultrasound and computed tomography in the staging of rectal cancer. Br J Surg 1988; 75:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/14\">",
"      Dershaw DD, Enker WE, Cohen AM, Sigurdson ER. Transrectal ultrasonography of rectal carcinoma. Cancer 1990; 66:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/15\">",
"      Jochem RJ, Reading CC, Dozois RR, et al. Endorectal ultrasonographic staging of rectal carcinoma. Mayo Clin Proc 1990; 65:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/16\">",
"      Katsura Y, Yamada K, Ishizawa T, et al. Endorectal ultrasonography for the assessment of wall invasion and lymph node metastasis in rectal cancer. Dis Colon Rectum 1992; 35:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/17\">",
"      Scialpi M, Andreatta R, Agugiaro S, et al. Rectal carcinoma: preoperative staging and detection of postoperative local recurrence with transrectal and transvaginal ultrasound. Abdom Imaging 1993; 18:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/18\">",
"      Fedyaev EB, Volkova EA, Kuznetsova EE. Transrectal and transvaginal ultrasonography in the preoperative staging of rectal carcinoma. Eur J Radiol 1995; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/19\">",
"      Waizer A, Powsner E, Russo I, et al. Prospective comparative study of magnetic resonance imaging versus transrectal ultrasound for preoperative staging and follow-up of rectal cancer. Preliminary report. Dis Colon Rectum 1991; 34:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/20\">",
"      Blomqvist L, Machado M, Rubio C, et al. Rectal tumour staging: MR imaging using pelvic phased-array and endorectal coils vs endoscopic ultrasonography. Eur Radiol 2000; 10:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/21\">",
"      Lindmark G, Elvin A, P&aring;hlman L, Glimelius B. The value of endosonography in preoperative staging of rectal cancer. Int J Colorectal Dis 1992; 7:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/22\">",
"      Hawes RH. New staging techniques. Endoscopic ultrasound. Cancer 1993; 71:4207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/23\">",
"      Mehta S, Johnson RJ, Schofield PF. Staging of colorectal cancer. Clin Radiol 1994; 49:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/24\">",
"      Kim HJ, Wong WD. Role of endorectal ultrasound in the conservative management of rectal cancers. Semin Surg Oncol 2000; 19:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/25\">",
"      Herzog U, von Fl&uuml;e M, Tondelli P, Schuppisser JP. How accurate is endorectal ultrasound in the preoperative staging of rectal cancer? Dis Colon Rectum 1993; 36:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/26\">",
"      Boyce GA, Sivak MV Jr, Lavery IC, et al. Endoscopic ultrasound in the pre-operative staging of rectal carcinoma. Gastrointest Endosc 1992; 38:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/27\">",
"      Beynon J, Mortensen NJ, Foy DM, et al. Preoperative assessment of mesorectal lymph node involvement in rectal cancer. Br J Surg 1989; 76:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/28\">",
"      Orrom WJ, Wong WD, Rothenberger DA, et al. Endorectal ultrasound in the preoperative staging of rectal tumors. A learning experience. Dis Colon Rectum 1990; 33:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/29\">",
"      Glaser F, Schlag P, Herfarth C. Endorectal ultrasonography for the assessment of invasion of rectal tumours and lymph node involvement. Br J Surg 1990; 77:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/30\">",
"      Milsom JW, Graffner H. Intrarectal ultrasonography in rectal cancer staging and in the evaluation of pelvic disease. Clinical uses of intrarectal ultrasound. Ann Surg 1990; 212:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/31\">",
"      Hulsmans FJ, Tio TL, Fockens P, et al. Assessment of tumor infiltration depth in rectal cancer with transrectal sonography: caution is necessary. Radiology 1994; 190:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/32\">",
"      Marusch F, Ptok H, Sahm M, et al. Endorectal ultrasound in rectal carcinoma--do the literature results really correspond to the realities of routine clinical care? Endoscopy 2011; 43:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/33\">",
"      Dixon AK, Fry IK, Morson BC, et al. Pre-operative computed tomography of carcinoma of the rectum. Br J Radiol 1981; 54:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/34\">",
"      Puli SR, Reddy JB, Bechtold ML, et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. Ann Surg Oncol 2009; 16:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/35\">",
"      Park HH, Nguyen PT, Tran Q, et al. Endoscopic ultrasound-guided fine needle aspiration in the staging of rectal cancer (abstract). Gastrointest Endosc 2000; 51:AB171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/36\">",
"      Wiersema MJ, Kochman ML, Cramer HM, et al. Endosonography-guided real-time fine-needle aspiration biopsy. Gastrointest Endosc 1994; 40:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/37\">",
"      Chang KJ, Nguyen P, Erickson RA, et al. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997; 45:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/38\">",
"      Rodriguez J, Kasberg C, Nipper M, et al. CT-guided needle biopsy of the pancreas: a retrospective analysis of diagnostic accuracy. Am J Gastroenterol 1992; 87:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/39\">",
"      Gress FG, Savides TJ, Sandler A, et al. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study. Ann Intern Med 1997; 127:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/40\">",
"      Wiersema MJ, Vilmann P, Giovannini M, et al. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 1997; 112:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/41\">",
"      Giovannini M, Seitz JF, Monges G, et al. Fine-needle aspiration cytology guided by endoscopic ultrasonography: results in 141 patients. Endoscopy 1995; 27:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/42\">",
"      Williams DB, Sahai AV, Aabakken L, et al. Endoscopic ultrasound guided fine needle aspiration biopsy: a large single centre experience. Gut 1999; 44:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/43\">",
"      Catalano MF, Alcocer E, Chak A, et al. Evaluation of metastatic celiac axis lymph nodes in patients with esophageal carcinoma: accuracy of EUS. Gastrointest Endosc 1999; 50:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/44\">",
"      Giovannini M, Monges G, Seitz JF, et al. Distant lymph node metastases in esophageal cancer: impact of endoscopic ultrasound-guided biopsy. Endoscopy 1999; 31:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/45\">",
"      Harewood GC. Assessment of clinical impact of endoscopic ultrasound on rectal cancer. Am J Gastroenterol 2004; 99:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/46\">",
"      Frasson M, Garcia-Granero E, Roda D, et al. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer 2011; 117:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/47\">",
"      Carmody BJ, Otchy DP. Learning curve of transrectal ultrasound. Dis Colon Rectum 2000; 43:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/48\">",
"      Mascagni D, Corbellini L, Urciuoli P, Di Matteo G. Endoluminal ultrasound for early detection of local recurrence of rectal cancer. Br J Surg 1989; 76:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/49\">",
"      Ramirez JM, Mortensen NJ, Takeuchi N, Humphreys MM. Endoluminal ultrasonography in the follow-up of patients with rectal cancer. Br J Surg 1994; 81:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/50\">",
"      Novell F, Pascual S, Viella P, Trias M. Endorectal ultrasonography in the follow-up of rectal cancer. Is it a better way to detect early local recurrence? Int J Colorectal Dis 1997; 12:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/51\">",
"      Maor Y, Nadler M, Barshack I, et al. Endoscopic ultrasound staging of rectal cancer: diagnostic value before and following chemoradiation. J Gastroenterol Hepatol 2006; 21:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/52\">",
"      Romagnuolo J, Parent J, Vuong T, et al. Predicting residual rectal adenocarcinoma in the surgical specimen after preoperative brachytherapy with endoscopic ultrasound. Can J Gastroenterol 2004; 18:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/53\">",
"      Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. Am J Gastroenterol 2004; 99:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/54\">",
"      Pastor C, Subtil JC, Sola J, et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? Dis Colon Rectum 2011; 54:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/55\">",
"      Rotondano G, Esposito P, Pellecchia L, et al. Early detection of locally recurrent rectal cancer by endosonography. Br J Radiol 1997; 70:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/56\">",
"      H&uuml;nerbein M, Totkas S, Moesta KT, et al. The role of transrectal ultrasound-guided biopsy in the postoperative follow-up of patients with rectal cancer. Surgery 2001; 129:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28967/abstract/57\">",
"      L&ouml;hnert MS, Doniec JM, Henne-Bruns D. Effectiveness of endoluminal sonography in the identification of occult local rectal cancer recurrences. Dis Colon Rectum 2000; 43:483.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2674 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-9A7ECFAA8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28967=[""].join("\n");
var outline_f28_18_28967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067157148\">",
"      T stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      N stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Fine needle aspiration biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067157171\">",
"      Circumferential resection margin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LEARNING CURVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RECURRENT RECTAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fine needle aspiration biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Follow-up after resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2674|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/11/15539\" title=\"diagnostic image 1\">",
"      Rectal cancer node EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/8/36993\" title=\"diagnostic image 2\">",
"      T2 rectal cancer EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/22/23905\" title=\"diagnostic image 3\">",
"      T3 rectal cancer EUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2674|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/17/3349\" title=\"picture 1\">",
"      T2 rectal ca EUS and Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2674|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=related_link\">",
"      Pretreatment local staging evaluation for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_18_28968="Endoscopic removal of large colonic polyps";
var content_f28_18_28968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic removal of large colonic polyps",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28968/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28968/contributors\">",
"     Uwe Seitz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28968/contributors\">",
"     Sabine Bohnacker, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28968/contributors\">",
"     Nib Soehendra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28968/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28968/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/18/28968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The removal of large colonic polyps during endoscopy raises a number of concerns, including the risk of the procedure and the possibility of inadequate polypectomy. The latter is particularly concerning, since large polyps have an increased risk of harboring invasive carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Endoscopic resection of large polyps, especially when sessile, is also significantly more time-consuming and requires more resources compared to polypectomy of smaller lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these issues, surgical resection may be used, particularly for large sessile polyps and for those in awkward locations. However, in many cases, proper technique applied by an experienced endoscopist can provide safe and adequate endoscopic treatment, avoiding the need for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on the principles and techniques for the colonoscopic removal of large polyps. The definition of \"large\" varies in the literature; for the purpose of this discussion, the definition of large will refer to polyps that are more than 2 cm in diameter. A discussion on the treatment and prevention of postpolypectomy bleeding is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11304?source=see_link\">",
"     \"Bleeding after colonic polypectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate patients for endoscopic removal of large polyps include those in whom the concern for malignancy is low, the size and location of the polyp is such that endoscopic removal is likely to be successful with a relatively low rate of complications,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient has underlying comorbidities that complicate surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Assessing for risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection should be considered when the macroscopic appearance of the polyp is not suspicious for malignancy (ie, the polyp is not friable, indurated, or ulcerated). On probing, the polyp should be soft and mobile against the bowel wall (",
"    <a class=\"graphic graphic_table graphicRef68868 \" href=\"UTD.htm?0/6/102\">",
"     table 1",
"    </a>",
"    ). Only 6 to 17 percent of polyps that fulfilled these criteria were malignant in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In one report, endoscopic palpation misclassified only 9 percent of approximately 1400 polyps, compared with a much higher misclassification rate (39 percent) with random biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic ultrasound (EUS) can also be helpful to assess for features suggesting malignancy (such as submucosal invasion or enlarged lymph nodes), particularly for sessile lesions in the rectum. Some authors use high frequency miniprobes that can be inserted through the biopsy channel of the colonoscope and thus applied in the entire colon. The use of EUS is at the discretion of the endoscopist and it is most often applied when submucosal invasion is suspected. EUS is not generally regarded as a prerequisite prior to polypectomy of large colorectal adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies alone to establish or exclude the presence of malignancy are inadequate (",
"    <a class=\"graphic graphic_figure graphicRef75488 \" href=\"UTD.htm?26/11/26814\">",
"     figure 1",
"    </a>",
"    ). Only complete excision permits accurate histological diagnosis. As a result, polypectomy should be considered primarily as a diagnostic procedure until histology confirms that the polyp has been completely removed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Polyp size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Having an unusually large polyp (even those more than 10 cm or with circumferential growth) is not a contraindication to endoscopic polypectomy. However, such polyps may require multiple sessions for removal, and subsequent surveillance is mandatory. These considerations should be explained to the patient.",
"   </p>",
"   <p>",
"    Some experts have suggested that polyps that occupy more than one third the circumference of the colon wall, cross two haustral folds, or involve the base of the appendix should be referred to either an expert endoscopist or a surgeon for removal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery may also be a better initial option for patients with multiple large polyps in the right colon, since these polyps usually require several endoscopic sessions and are associated with increased procedural risk. Endoscopic polypectomy should not be performed if circumstances do not permit repeated treatment and follow-up sessions. Furthermore, it should not be attempted in patients with uncorrectable bleeding disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of techniques for endoscopic excision of large polyps have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/18\">",
"     18",
"    </a>",
"    ]. The optimal method has not yet been established based upon large controlled trials with adequate follow-up. Thus, the endoscopic approach depends upon characteristics and location of the polyp and the endoscopist's experience. The following section will review some of the approaches that have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Snare polypectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most large pedunculated polyps can be removed by transection of the stalk with a polypectomy snare using electrocautery (",
"    <a class=\"graphic graphic_picture graphicRef53630 \" href=\"UTD.htm?30/15/30960\">",
"     picture 1",
"    </a>",
"    ). The major risk with this approach is postpolypectomy bleeding. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endoscopic mucosal resection using piecemeal excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Piecemeal excision using standard electrocautery techniques is commonly used to remove large sessile polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/1-3,5,19\">",
"     1-3,5,19",
"    </a>",
"    ]. Polyps are considered to be sessile if the base of the polyp is attached to the colonic wall. High-resolution endoscopes with high-definition monitors allow for clear visualization of the polyp margins in most cases, but sometimes it can be difficult to appreciate the extent of such lesions. Some endoscopists use dye (such as 0.1 to 1.0 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    solution) for better identification of the margins (chromoendoscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/8,9,20,21\">",
"     8,9,20,21",
"    </a>",
"    ]. An alternative to chromoendoscopy is to visualize the polyp under blue light (narrow band imaging), which enhances differences between polyp and normal mucosa (",
"    <a class=\"graphic graphic_picture graphicRef87242 \" href=\"UTD.htm?19/34/20006\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link&amp;anchor=H2#H2\">",
"     \"Narrow band imaging in Barrett's esophagus\", section on 'Principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that sessile polyps larger than 2 cm be resected in a piecemeal fashion to avoid perforation, and some experts have suggested that any polyp greater than 1.5 cm be resected piecemeal (",
"    <a class=\"graphic graphic_picture graphicRef62455 \" href=\"UTD.htm?9/8/9348\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Resection technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polyp should be oriented at the six o'clock position, which corresponds to the operating channel of the endoscope. The polyp is then ensnared and cautery applied to resect tissue. We use pure coagulation or Endo-Cut current applied in bursts. Every part ensnared should be lifted away from the wall before application of current to prevent deep coagulation, which is associated with an increased risk of perforation.",
"   </p>",
"   <p>",
"    If a sessile polyp covers a fold, both sides of the fold have to be cleared separately. The cephalad side may be difficult to visualize and maneuvers such as lifting of the lesion by well-directed submucosal injection (saline or epinephrine 1:20,000 to 100,000) or working in a retroflexed position may help [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/22\">",
"     22",
"    </a>",
"    ]. If saline injection is used, it is important to start with the cephalad side of the polyp, as the cephalad side can be difficult to access once the caudad side of the polyp has been raised. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Submucosal injection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of a stiff monofilament snare can greatly facilitate resection since it allows for spreading out the fold. The tip is placed behind the fold and opened to gently push on the mucosa and flatten out the fold, exposing the polyp. The snare is then slowly closed and the catheter advanced simultaneously to keep the tip in position. It is important to maneuver the snare parallel to the surface to avoid cutting too deeply. Suction should be avoided while closing the snare.",
"   </p>",
"   <p>",
"    Resection should be performed systematically, beginning at one margin. Once the muscle layer has been exposed, further resection steps should be performed from there. Attempts should be made to avoid leaving islets of adenomatous tissue between resected pieces, since they may be difficult to ensnare later, requiring the use of argon plasma coagulation (APC) and increasing the risk of recurrence. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment of residual adenoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following piecemeal resection, the polypectomy site should have a clean surface. Some authorities have advocated staining with dyes such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    to highlight areas of residual tissue. High resolution endoscopes can help identify small areas of remnant tissue (",
"    <a class=\"graphic graphic_picture graphicRef87246 \" href=\"UTD.htm?31/7/31862\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We prefer to not tattoo routinely at the initial procedure if complete resection and benign histology are highly probable, but will instead repeat a colonoscopy for tattooing within two weeks (to ensure that the polypectomy site will still be visible) if pathology reveals the (possible) need for subsequent surgery. However, some endoscopists choose to tattoo all large polypectomy sites at the initial procedure. Tattooing is best performed by injecting India ink on two contralateral sides of the bowel wall to allow for fast identification at surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=see_link\">",
"     \"Tattooing and other methods for localizing colonic lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Submucosal injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of normal saline into the submucosa prior to polypectomy has been proposed to raise large sessile polyps, thereby reducing the risk of perforation during subsequent snare excision (",
"    <a class=\"graphic graphic_picture graphicRef70345 \" href=\"UTD.htm?31/61/32721\">",
"     picture 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/4,23,24\">",
"     4,23,24",
"    </a>",
"    ]. Experts have suggested that any sessile polyp larger than 1.5 cm that is located proximal to the rectum be removed following saline lift [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/17\">",
"     17",
"    </a>",
"    ]. Adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    to the saline may aid in defining the borders of a sessile adenoma. However, some endoscopists avoid saline injection since it can distort the anatomy. Failure of the polyp to lift with saline injection raises concern for malignancy.",
"   </p>",
"   <p>",
"    Several studies have described outcomes using saline lift techniques. One study suggested that the penetration depth of ulcers due to electrocautery was shallower with previous submucosal saline injection than without saline injection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/23\">",
"     23",
"    </a>",
"    ]. Whether this benefit translates into a lower risk of perforation and bleeding and more complete excision than other approaches has not been well established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some endoscopists will use diluted epinephrine to lift polyps to decrease postprocedural bleeding. However, it is unclear whether diluted epinephrine is more efficient in the prevention of postprocedural bleeding than saline or other agents such as hyaluronic acid&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clipping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have evaluated the use of clipping as a prophylactic measure after polypectomy to prevent bleeding, with conflicting results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized controlled trial of 413 patients, the routine use of hemoclips to close small postpolypectomy ulcers did not reduce bleeding rates, even if a visible vessel was present [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study examined 263 endoscopic resections of polyps that were at least 2 cm in maximal dimension. Delayed bleeding occurred in 6 percent of patients, and was more common in polypectomies where prophylactic measures like clips on visible vessels were not used [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second retrospective study also looked at endoscopic resections of polyps that were at least 2 cm in size [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/28\">",
"       28",
"      </a>",
"      ]. A total of 524 polyps were removed, 277 of which received prophylactic clips. There was a decreased risk of delayed bleeding among patients whose polypectomy sites were prophylactically clipped compared with those who did not undergo prophylactic clipping (2 versus 10 percent, adjusted odds ratio 6.0, 95% confidence interval 2.0-19).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment of residual adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remnants of adenomatous tissue at the margin of the resection site can be removed with a biopsy forceps or treated with argon plasma coagulation (power limit 60W, Argon flow 1 to 2 liters per minute) or other forms of monopolar coagulation (pure coagulation, power limit 60W) (",
"    <a class=\"graphic graphic_picture graphicRef87246 \" href=\"UTD.htm?31/7/31862\">",
"     picture 4",
"    </a>",
"    ). However, coagulation of large areas of the adenoma should be avoided, since the subsequent scarring may hamper snare mucosectomy during repeat endoscopy. Furthermore, complete histological assessment of the lesion is precluded by fulguration of large parts of the polyp",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Specimen collection and histologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete assessment of the resected tissue is required for accurate diagnosis. This may be cumbersome if a large number of pieces are obtained during piecemeal resection. If the pieces are relatively small, they can be suctioned through the working channel and collected in a trap. Otherwise they may be removed using a Roth retrieval net (US Endoscopy Group, Inc., 5976 Heisley Road, Mentor, Ohio 44060). This device can be opened and closed repeatedly until all the fragments of the polyps have been collected. The polyp tissue is then withdrawn along with the endoscope (",
"    <a class=\"graphic graphic_picture graphicRef62455 \" href=\"UTD.htm?9/8/9348\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Histologic evaluation may be more difficult after piecemeal resection. In the case of a benign adenoma, however, correct diagnosis is usually possible if all the pieces are collected. In the presence of cancer within an adenoma, complete resection with clean margins may still be diagnosed if the cancer is focal and contained entirely in one fragment. If margins cannot be clearly assessed, short-term endoscopic follow-up with biopsies may help to confirm absence or presence of tumor remnants. In case of doubt, subsequent surgical resection should be performed in operable patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Efficacy of EMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of conventional piecemeal endoscopic mucosal resection (EMR) for benign sessile colorectal adenomas has been established over many years. When used appropriately, the rate of lesions containing invasive carcinoma is usually under 10 percent. When follow-up examinations are performed in a timely manner, any recurrent adenoma is usually benign and can frequently be successfully managed using the same technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have illustrated the therapeutic possibilities of conventional piecemeal EMR, even for very large lesions. However, they also underscore the need for careful patient selection and high endoscopic expertise to achieve good results and manage complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report focused on 136 large polyps that were removed by piecemeal resection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/29\">",
"       29",
"      </a>",
"      ]. Of these, 24 polyps (18 percent) had macroscopically evident residual adenoma at first follow-up and six had recurrent adenoma at later follow-up. The likelihood of a late recurrence was only 2 percent in patients with no visible adenoma and negative biopsy results of the scar at the first follow-up.",
"     </li>",
"     <li>",
"      A second study included 186 endoscopically resected polyps between 3 and 13 cm in maximum diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/3\">",
"       3",
"      </a>",
"      ]. Of 141 sessile polyps, 121 were excised in a single session using a piecemeal technique. Two patients required surgery for procedural bleeding and one for delayed perforation in the cecum. Four cases of delayed bleeding were managed endoscopically. During a mean follow-up of 40 months, benign recurrences were observed in only 3 percent of patients and there was only a single case of a malignant recurrence. The authors used clips to prevent bleeding and argon plasma coagulation for any milky or semitransparent tissue (suspected submucosa) overlying the muscularis propria to reduce the recurrence rate.",
"     </li>",
"     <li>",
"      A third study of 148 polyps ranging from 20 to 100 mm in size that were removed either piecemeal or en bloc had an overall recurrence rate of 4.2 percent after a mean of 30 months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/30\">",
"       30",
"      </a>",
"      ]. Recurrence was more common in patients with polyps 40 mm in size or greater compared to those with smaller polyps (14 percent versus to 1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of recurrence increases with the amount of tissue left for coagulation after snare resection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and studies looking at recurrence rates following APC have had mixed results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial of 21 patients suggested that APC may decrease recurrence following piecemeal resection of large (greater than 1.5 cm) sessile adenomas that were thought to have been completely resected [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective uncontrolled study of 136 patients undergoing piecemeal resection, recurrence rates were the same with and without APC [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endoscopic submucosal dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic submucosal dissection (ESD) is a resection technique for early gastrointestinal tract cancers. Currently, it is used mainly in the stomach, but it is being applied increasingly in the colon and rectum. The aim of ESD is to achieve an en-bloc resection of a sessile lesion, irrespective of its size. This facilitates histological evaluation and improves rates of curative resection, even for carcinoma with early submucosal invasion. The technique involves submucosal injection and circumferential dissection of the tumor-bearing mucosa and submucosa using various diathermic knives.",
"   </p>",
"   <p>",
"    Multiple studies have shown high rates of successful polyp resection with ESD. A meta-analysis of 14 studies found a successful en-bloc resection rate of 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/34\">",
"     34",
"    </a>",
"    ]; in 75 percent of the procedures, the resection margins were histologically negative for adenoma.",
"   </p>",
"   <p>",
"    Studies have demonstrated lower recurrence rates following ESD with en-bloc resection compared to piecemeal EMR (0 to 2 percent compared to 6 to 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, this is achieved at the cost of long procedure times (up to 290 minutes have been reported).",
"   </p>",
"   <p>",
"    Complication rates are also higher with ESD compared to EMR. Perforations occur in up to 10 percent of procedures, though frequently they can be managed by endoscopic clipping and conservative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, surgery is still required in some cases. Even for uncomplicated cases, prolonged hospital stays of up to five days are common following ESD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the fact that ESD is being performed increasingly in the upper and lower GI tract, the role of ESD in the colon has not yet been clearly established. However, with increasing expertise worldwide and the development of modified equipment and techniques allowing for safer, easier, and faster procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/39-43\">",
"     39-43",
"    </a>",
"    ], ESD will likely become established as a valuable tool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedural bleeding immediately after polypectomy is usually minor and not necessarily regarded as a complication, but significant bleeding can occur either at the time of the procedure or several days later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11304?source=see_link\">",
"     \"Bleeding after colonic polypectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not routinely hospitalize patients undergoing endoscopic resection of large polyps since delayed bleeding following polypectomy can occur after more than a week. An exception is a patient who is anticoagulated. If delayed bleeding occurs, there is usually enough time for the patient to come back for emergency endoscopy. In our experience, delayed bleeding requiring hospitalization has become rare due to improvement in endoscopic measures aimed at prevention of bleeding (",
"    <a class=\"graphic graphic_picture graphicRef72550 \" href=\"UTD.htm?36/24/37251\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56809 \" href=\"UTD.htm?9/52/10051\">",
"     picture 7",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clipping'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforation is the most serious complication of polyp removal, but it can usually be prevented by adherence to careful technique. For standard colonoscopy and polypectomy perforations are rare (0 to 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/1-5,23,30,33\">",
"     1-5,23,30,33",
"    </a>",
"    ]. However, as noted above, the rate may be as high as 10 percent with endoscopic submucosal dissection.",
"   </p>",
"   <p>",
"    The following should be kept in mind when performing endoscopic polypectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ensnaring of a colonic fold must be carefully avoided. Large pedunculated or sessile lesions can initially obscure the anatomy. Thus, resection should only be carried out if the ensnared portion can be clearly visualized.",
"     </li>",
"     <li>",
"      Delayed perforation may occur due to the spread of thermal injury to the deeper layers of the bowel wall. This can occur if a pedunculated polyp is resected too near to the bowel wall, leaving no residual stalk. This can also happen if an ensnared polyp is not lifted into the lumen of the bowel before current is applied.",
"     </li>",
"     <li>",
"      The snare has to be closed tightly before applying coagulation, since thermal injury with delayed perforation may occur if the tip of the snare inadvertently touches the bowel wall behind the polyp. Sometimes this cannot be accomplished without cutting through the polyp. However, it is safer to transect a polyp mechanically (ie, without coagulation), since the major risk will be bleeding, which usually occurs immediately and can be controlled endoscopically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgery is usually indicated if perforation occurs. However, since the bowel is usually clean at the time of the polypectomy, it may be safe to close a small or only suspected perforation using clips, thus allowing for conservative management. We do not attempt this in patients, however, in whom air flows quickly into the peritoneal cavity. Patients treated conservatively should be observed closely for one week. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up examinations are mandatory after endoscopic resection of large adenomas, since recurrence rates of up to 50 percent have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/8,9,31,32,44,45\">",
"     8,9,31,32,44,45",
"    </a>",
"    ]. In some studies with high recurrence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], the first follow-up examination was performed after three to six months, suggesting the possibility of adenoma remnants rather than recurrence. This underscores the necessity of short-term follow-up examinations to look for and treat remaining adenomatous tissue. Follow-up examinations should be repeated until a clean scar can be confirmed. The term \"recurrence\" should only be used if complete removal of the entire lesion has been established.",
"   </p>",
"   <p>",
"    Subsequent follow-up will depend on the polyp's size and histologic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125359949#H125359949\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Management of carcinoma in a polyp'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommended follow-up protocol depends on the manner of resection and histology. Following piecemeal resection and in the absence of invasive carcinoma, we perform short-term follow-up examinations at four- to six-week intervals to rule out or treat remnant neoplastic tissue until a clean scar is visible. According to published guidelines, in many cases, once the entire polyp has been removed, the next follow-up examination should be performed in three years, followed by five-year intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28968/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .) However, in our experience, more frequent follow-up examinations (one- to three-year intervals) should be considered, especially for patients with extensive lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent adenomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=see_link\">",
"       \"Patient information: Colon polyps (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"       \"Patient information: Colon polyps (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion represents our approach based upon the available data and our experience.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest sessile polyps larger than 2 cm be resected in a piecemeal fashion to decrease the risk of perforation (",
"      <a class=\"graphic graphic_picture graphicRef62455 \" href=\"UTD.htm?9/8/9348\">",
"       picture 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Pedunculated polyps are generally treated using standard snare polypectomy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Endoscopic mucosal resection using piecemeal excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following successful piecemeal resection, the polypectomy site should demonstrate a clean surface. For extensive lesions, several sessions in four to six week intervals may be required to achieve this. Staining or endoscopic contrast enhancement may be helpful for assessment of resection margins.",
"     </li>",
"     <li>",
"      We treat small remnants of adenomatous tissue at the margin of the resection site with argon plasma coagulation or other monopolar coagulation (",
"      <a class=\"graphic graphic_picture graphicRef87246 \" href=\"UTD.htm?31/7/31862\">",
"       picture 4",
"      </a>",
"      ). However, coagulation of large areas of the adenoma should be avoided. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Endoscopic mucosal resection using piecemeal excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pedunculated polyps with a wide stalk, or if a visible vessel is seen, we suggest employing prophylactic measures to decrease the risk hemorrhage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Hemoclips are safer than thermal methods since they do not provoke bleeding and do not cause further tissue necrosis (",
"      <a class=\"graphic graphic_picture graphicRef53630 \" href=\"UTD.htm?30/15/30960\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clipping'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If margins cannot be clearly assessed histologically after piecemeal resection of an adenoma containing invasive carcinoma, we suggest short-term endoscopic follow-up with biopsies to confirm absence or presence of tumor remnants. In case of doubt, we suggest surgical resection in operable patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once all of the polyp tissue has been removed, additional follow-up is dependent upon the histologic findings. Extensive size of the initial lesion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent adenoma may warrant frequent follow-up examinations. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Follow-up'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"       \"Approach to the patient with colonic polyps\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125359949#H125359949\">",
"       \"Surgical oncologic principles for the resection of colon cancer\", section on 'Management of carcinoma in a polyp'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/1\">",
"      Binmoeller KF, Bohnacker S, Seifert H, et al. Endoscopic snare excision of \"giant\" colorectal polyps. Gastrointest Endosc 1996; 43:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/2\">",
"      Walsh RM, Ackroyd FW, Shellito PC. Endoscopic resection of large sessile colorectal polyps. Gastrointest Endosc 1992; 38:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/3\">",
"      Doniec JM, L&ouml;hnert MS, Schniewind B, et al. Endoscopic removal of large colorectal polyps: prevention of unnecessary surgery? Dis Colon Rectum 2003; 46:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/4\">",
"      Kanamori T, Itoh M, Yokoyama Y, Tsuchida K. Injection-incision--assisted snare resection of large sessile colorectal polyps. Gastrointest Endosc 1996; 43:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/5\">",
"      Boix J, Lorenzo-Z&uacute;&ntilde;iga V, Moreno de Vega V, et al. Endoscopic removal of large sessile colorectal adenomas: is it safe and effective? Dig Dis Sci 2007; 52:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/6\">",
"      Overhiser AJ, Rex DK. Work and resources needed for endoscopic resection of large sessile colorectal polyps. Clin Gastroenterol Hepatol 2007; 5:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/7\">",
"      Galandiuk S, Fazio VW, Jagelman DG, et al. Villous and tubulovillous adenomas of the colon and rectum. A retrospective review, 1964-1985. Am J Surg 1987; 153:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/8\">",
"      Tanaka S, Haruma K, Oka S, et al. Clinicopathologic features and endoscopic treatment of superficially spreading colorectal neoplasms larger than 20 mm. Gastrointest Endosc 2001; 54:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/9\">",
"      Hurlstone DP, Sanders DS, Cross SS, et al. Colonoscopic resection of lateral spreading tumours: a prospective analysis of endoscopic mucosal resection. Gut 2004; 53:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/10\">",
"      Morson BC. Histological criteria for local excision. Br J Surg 1985; 72 Suppl:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/11\">",
"      Hermanek P. Malignant polyps--pathological factors governing clinical management. Curr Top Pathol 1990; 81:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/12\">",
"      Kikuchi R, Takano M, Takagi K, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995; 38:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/13\">",
"      Hackelsberger A, Fr&uuml;hmorgen P, Weiler H, et al. Endoscopic polypectomy and management of colorectal adenomas with invasive carcinoma. Endoscopy 1995; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/14\">",
"      Cranley JP, Petras RE, Carey WD, et al. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma? Gastroenterology 1986; 91:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/15\">",
"      Cooper HS, Deppisch LM, Kahn EI, et al. Pathology of the malignant colorectal polyp. Hum Pathol 1998; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/16\">",
"      Netzer P, Binek J, Hammer B, et al. Significance of histologic criteria for the management of patients with malignant colorectal polyps and polypectomy. Scand J Gastroenterol 1997; 32:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/17\">",
"      Waye JD. Advanced polypectomy. Gastrointest Endosc Clin N Am 2005; 15:733.",
"     </a>",
"    </li>",
"    <li>",
"     Soehendra N, Binmoeller KF, Seifert S, et al. Therapeutic Endoscopy, 1st Ed, Thieme Verlag, Hamburg, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/19\">",
"      Bardan E, Bat L, Melzer E, et al. Colonoscopic resection of large colonic polyps--a prospective study. Isr J Med Sci 1997; 33:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/20\">",
"      Uraoka T, Kato J, Ishikawa S, et al. Thin endoscope-assisted endoscopic submucosal dissection for large colorectal tumors (with videos). Gastrointest Endosc 2007; 66:836.",
"     </a>",
"    </li>",
"    <li>",
"     Kudo S. Early colorectal cancer, 1st Ed, Igaku-Shoin, Tokyo 1996. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/22\">",
"      Rex DK, Khashab M. Colonoscopic polypectomy in retroflexion. Gastrointest Endosc 2006; 63:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/23\">",
"      Iishi H, Tatsuta M, Iseki K, et al. Endoscopic piecemeal resection with submucosal saline injection of large sessile colorectal polyps. Gastrointest Endosc 2000; 51:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/24\">",
"      Shirai M, Nakamura T, Matsuura A, et al. Safer colonoscopic polypectomy with local submucosal injection of hypertonic saline-epinephrine solution. Am J Gastroenterol 1994; 89:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/25\">",
"      Lee SH, Chung IK, Kim SJ, et al. Comparison of postpolypectomy bleeding between epinephrine and saline submucosal injection for large colon polyps by conventional polypectomy: a prospective randomized, multicenter study. World J Gastroenterol 2007; 13:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/26\">",
"      Shioji K, Suzuki Y, Kobayashi M, et al. Prophylactic clip application does not decrease delayed bleeding after colonoscopic polypectomy. Gastrointest Endosc 2003; 57:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/27\">",
"      Church JM. Experience in the endoscopic management of large colonic polyps. ANZ J Surg 2003; 73:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/28\">",
"      Liaquat H, Rohn E, Rex DK. Prophylactic clip closure reduced the risk of delayed postpolypectomy hemorrhage: experience in 277 clipped large sessile or flat colorectal lesions and 247 control lesions. Gastrointest Endosc 2013; 77:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/29\">",
"      Khashab M, Eid E, Rusche M, Rex DK. Incidence and predictors of \"late\" recurrences after endoscopic piecemeal resection of large sessile adenomas. Gastrointest Endosc 2009; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/30\">",
"      Luigiano C, Consolo P, Scaffidi MG, et al. Endoscopic mucosal resection for large and giant sessile and flat colorectal polyps: a single-center experience with long-term follow-up. Endoscopy 2009; 41:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/31\">",
"      Zlatanic J, Waye JD, Kim PS, et al. Large sessile colonic adenomas: use of argon plasma coagulator to supplement piecemeal snare polypectomy. Gastrointest Endosc 1999; 49:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/32\">",
"      Brooker JC, Saunders BP, Shah SG, et al. Treatment with argon plasma coagulation reduces recurrence after piecemeal resection of large sessile colonic polyps: a randomized trial and recommendations. Gastrointest Endosc 2002; 55:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/33\">",
"      Conio M, Repici A, Demarquay JF, et al. EMR of large sessile colorectal polyps. Gastrointest Endosc 2004; 60:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/34\">",
"      Puli SR, Kakugawa Y, Saito Y, et al. Successful complete cure en-bloc resection of large nonpedunculated colonic polyps by endoscopic submucosal dissection: a meta-analysis and systematic review. Ann Surg Oncol 2009; 16:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/35\">",
"      Saito Y, Fukuzawa M, Matsuda T, et al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg Endosc 2010; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/36\">",
"      Tamegai Y, Saito Y, Masaki N, et al. Endoscopic submucosal dissection: a safe technique for colorectal tumors. Endoscopy 2007; 39:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/37\">",
"      Fujishiro M, Yahagi N, Kakushima N, et al. Successful nonsurgical management of perforation complicating endoscopic submucosal dissection of gastrointestinal epithelial neoplasms. Endoscopy 2006; 38:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/38\">",
"      Yoshida N, Wakabayashi N, Kanemasa K, et al. Endoscopic submucosal dissection for colorectal tumors: technical difficulties and rate of perforation. Endoscopy 2009; 41:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/39\">",
"      Toyonaga T, Man-I M, Morita Y, et al. The new resources of treatment for early stage colorectal tumors: EMR with small incision and simplified endoscopic submucosal dissection. Dig Endosc 2009; 21 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/40\">",
"      Sakamoto N, Osada T, Shibuya T, et al. Endoscopic submucosal dissection of large colorectal tumors by using a novel spring-action S-O clip for traction (with video). Gastrointest Endosc 2009; 69:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/41\">",
"      Yahagi N, Neuhaus H, Schumacher B, et al. Comparison of standard endoscopic submucosal dissection (ESD) versus an optimized ESD technique for the colon: an animal study. Endoscopy 2009; 41:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/42\">",
"      Fujishiro M, Yahagi N, Nakamura M, et al. Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc 2006; 63:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/43\">",
"      K&auml;hler GF, Sold MS, Post S, et al. Selective tissue elevation by pressure injection (STEP) facilitates endoscopic mucosal resection (EMR). Surg Technol Int 2007; 16:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/44\">",
"      Stergiou N, Riphaus A, Lange P, et al. Endoscopic snare resection of large colonic polyps: how far can we go? Int J Colorectal Dis 2003; 18:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/45\">",
"      Nivatvongs S, Snover DC, Fang DT. Piecemeal snare excision of large sessile colon and rectal polyps: is it adequate? Gastrointest Endosc 1984; 30:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28968/abstract/46\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134:1570.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2577 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28968=[""].join("\n");
var outline_f28_18_28968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Assessing for risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Polyp size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Snare polypectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endoscopic mucosal resection using piecemeal excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Resection technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Submucosal injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clipping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment of residual adenoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Specimen collection and histologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Efficacy of EMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endoscopic submucosal dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2577|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/11/26814\" title=\"figure 1\">",
"      Malignant polyp biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2577|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/15/30960\" title=\"picture 1\">",
"      Polypectomy short stalk Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/34/20006\" title=\"picture 2\">",
"      Rectal adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/8/9348\" title=\"picture 3\">",
"      Resection sessile polyp Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/7/31862\" title=\"picture 4\">",
"      Colon polyp piecemeal excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/61/32721\" title=\"picture 5\">",
"      Endoloop and hemoclip Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/24/37251\" title=\"picture 6\">",
"      Polypectomy APC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/52/10051\" title=\"picture 7\">",
"      Prophylactic hemoclip Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2577|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/6/102\" title=\"table 1\">",
"      Endoscopic criteria malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11304?source=related_link\">",
"      Bleeding after colonic polypectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=related_link\">",
"      Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=related_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=related_link\">",
"      Patient information: Colon polyps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=related_link\">",
"      Tattooing and other methods for localizing colonic lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_18_28969="Treatment of chronic pelvic pain in women";
var content_f28_18_28969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic pelvic pain in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28969/contributors\">",
"     Fred Howard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28969/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28969/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/18/28969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Success in treating women with chronic pelvic pain (CPP) is greatly facilitated by earning their trust and confidence. This is best accomplished by performing a thorough evaluation, and by listening to them, validating that their pain is \"real,\" offering explanations and reassurance, and making a commitment to try to help [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients are able to understand that there are no \"magic bullets\" or instant cures and are satisfied with the knowledge that their physicians will make an honest effort to help them in a gradual and stepwise fashion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Usually the history and physical examination suggest one or more diagnoses or disorders (\"pain generators\") that seem to cause or exacerbate CPP (",
"    <a class=\"graphic graphic_table graphicRef58699 \" href=\"UTD.htm?4/49/4893\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To decide on the best therapeutic plan for an individual patient, the physician and patient should have a thorough discussion of her preferences and values regarding testing, medical versus surgical treatment, and childbearing plans. For many patients, the optimal approach involves a combination of treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Empiric trial of therapy based on diagnostic probabilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to managing women with CPP is to prescribe sequential drug treatments for disorders that are the most likely causes of the patient's CPP. As an example, endometriosis is the most common gynecological cause of CPP. If endometriosis seems a likely diagnosis based upon the history and physical examination, then a medical therapy for endometriosis is given for a trial period (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Endometriosis'",
"    </a>",
"    below). If this is not successful, then a trial of another medical therapy is initiated. If one of these treatments relieves the pelvic pain, then the likelihood that endometriosis is the cause of CPP increases. However, it is important to note that improvement in symptoms is not absolute confirmation of a diagnosis since treatment effects are often not specific. As an example, hormonal treatment of endometriosis may also improve pelvic congestion syndrome, irritable bowel syndrome, or interstitial",
"    <span class=\"nowrap\">",
"     cystitis/painful",
"    </span>",
"    bladder syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intensive diagnostic evaluation followed by targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A different approach is to use intensive diagnostic testing in an attempt to identify the specific cause of the patient's CPP, if possible, before starting specific therapy. Although therapy targeted specifically to the patient's diagnosis might appear ideal, arriving at a diagnosis may involve costly laboratory and imaging tests, and often requires exploratory surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonspecific analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third option is treatment directed at pain, rather than at a specific diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EMPIRIC TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the diagnostic impression is most consistent with endometriosis after a complete initial evaluation, then most experts consider empiric medical therapy without surgical confirmation a safe and effective approach. As discussed above, a satisfactory response to empiric treatment cannot be construed as definitive confirmation or exclusion of the diagnosis of endometriosis. Definitive diagnosis requires histological confirmation of ectopic endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First line agents employed sequentially include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) prescribed at maximal doses (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      800 mg orally every eight hours). If the first NSAID given is not effective after four to six weeks, another should be tried because of variability in response among individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"       \"NSAIDs: Therapeutic use and variability of response in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral contraceptive pills (OCs) prescribed as monthly cycles for two to three months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/7\">",
"       7",
"      </a>",
"      ]. If the patient has not had significant side effects from NSAIDS, then the NSAIDS should be continued.",
"     </li>",
"     <li>",
"      OCs prescribed continuously, that is, without a break to allow menstrual flow. This regimen has been effective in women who failed cyclic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the combination of NSAIDS and continuous OCs is unsuccessful after two to three months, then second line agents should be tried.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous progestin treatments that have shown efficacy in randomized clinical trials include [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/9-13\">",
"       9-13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       Medroxyprogesterone acetate",
"      </a>",
"      (initially at 10 mg daily and may increase up to 50 mg orally daily depending on tolerance).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       Norethindrone acetate",
"      </a>",
"      (initially at 2.5 mg orally daily and may increase to 30 mg orally daily).",
"     </li>",
"     <li>",
"      Subcutaneous depo-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , 104 mg every three months.",
"     </li>",
"     <li>",
"      A levonorgestrel-releasing intrauterine system. In a randomized clinical trial, this device reduced pelvic pain in women with endometriosis with similar success as a GnRH agonist [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonadotropin releasing hormone (GnRH) agonist (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      acetate 3.75 mg intramuscularly every four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/15\">",
"       15",
"      </a>",
"      ] or 11.25 mg intramuscularly every 12 weeks). An appropriate add-back regimen should be considered to minimize side effects, but is especially important to avoid loss of bone mineral density if therapy is to be continued for six or more months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"      200 to 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      total divided into two doses. The dose may be increased to a total dose of 800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to achieve amenorrhea and rapid response to painful symptoms. Therapy should be continued uninterrupted for two months and, if successful, may be continued up to nine months. Side effects are a disadvantage to this therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical evaluation and treatment via laparoscopy is the next option if empiric medical interventions are not successful. Surgery can be performed instead of empiric medical therapy if the patient prefers, and should be the initial approach if a pelvic mass is detected (to exclude neoplasia).",
"   </p>",
"   <p>",
"    A detailed discussion of medical, surgical, and combined treatment of endometriosis can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"     \"Overview of the treatment of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TARGETED TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted therapy is appropriate if a specific diagnosis has been made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic options are briefly summarized below, and discussed in detail separately. The American College of Obstetricians and Gynecologists' recommendations for treatment of CPP are described in the table (",
"    <a class=\"graphic graphic_table graphicRef71859 graphicRef82431 \" href=\"UTD.htm?9/16/9485\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Irritable bowel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications in diet, behavioral changes, medications, and psychotherapy are utilized alone or in combination, based on the severity of symptoms. A detailed discussion of the treatment of IBS can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"     \"Treatment of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interstitial cystitis/painful bladder syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the currently available therapies for this disorder are curative. Ongoing physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacologic therapies are prescribed to achieve remission. A detailed discussion of the treatment of interstitial cystitis is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best available evidence showed adhesiolysis is not effective for relieving chronic pain in most women with CPP or chronic abdominal pain, although observational studies have suggested efficacy. This conclusion was supported by the following randomized controlled trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 48 women with CPP were randomly assigned to surgical adhesiolysis of abdominopelvic adhesions or expectant management [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/17\">",
"       17",
"      </a>",
"      ]. Prior to randomization, all women had a laparoscopy procedure to stage the severity of the adhesions using the criteria of Kapur [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/18\">",
"       18",
"      </a>",
"      ]. Pain was assessed using the McGill pain questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Women with previous malignant pelvic disease, hormonal treatment for pelvic pain, or psychiatric treatment during the previous two years were excluded.",
"      <br/>",
"      <br/>",
"      One year later, approximately 50 percent of women in both groups reported improvement in their pain. However, a post-hoc analysis revealed that women with dense vascularized adhesions involving the bowel and peritoneum had a significantly greater degree of pain relief with adhesiolysis than with expectant management.",
"     </li>",
"     <li>",
"      The lack of benefit of adhesiolysis was confirmed in another trial in which 100 patients with laparoscopically documented adhesions and chronic abdominal (not pelvic) pain were randomly assigned at the time of diagnostic laparoscopy to either adhesiolysis or no adhesiolysis (controls) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients were not told of their assignment until the study was over, 12 months after the surgical procedure. Assessors unaware of the patient's allocation evaluated pain using a visual analogue score (VAS) score (scale 0 to 100), pain change score, use of analgesics, and quality of life score.",
"      <br/>",
"      <br/>",
"      Fewer patients in the adhesiolysis group than the control group reported no change or worsened pain (43 versus 58 percent), but the difference did not reach statistical significance. There was no difference between groups in quality of life or VAS scores after one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These randomized clinical trials suggest that surgical adhesiolysis is not likely to benefit women with CPP, except possibly those with dense vascularized adhesions, especially when involving bowel. The absence of a significant benefit from adhesiolysis may be due to the high rate (greater than 70 percent) of",
"    <span class=\"nowrap\">",
"     reformation/new",
"    </span>",
"    formation of adhesions after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], or it may be because adhesions are not the source of the patient's pain. Since adhesiolysis can have significant complications, such as bowel perforation and postoperative new adhesiogenesis, its use as a treatment for CPP is not generally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Myofascial pain syndrome (trigger point pain)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although abdominal and pelvic myofascial pain and focal tender points consistent with trigger points are often noted in patients with CPP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/26\">",
"     26",
"    </a>",
"    ], treatment of this condition is based on anecdotal clinical experience, not rigorous clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40389?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=see_link\">",
"     \"Treatment of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approaches that we think are most effective for myofascial pain include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical therapy (icing, moist heat, stretching, massage, ultrasound, transcutaneous electrical stimulation, galvanic muscle stimulation, biofeedback). Evaluation and treatment by a physical therapist or physician trained in musculoskeletal disorders in women's health care is ideal, if available [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. A randomized clinical trial comparing myofascial physical therapy to a control group treated with global therapeutic massage for the treatment of urological CPP reported response rates of 57 and 21 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33127?source=see_link\">",
"       \"Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trigger point injections &mdash; The skin over the trigger point is stretched between two fingers, then a 2.5 inch 22 or 25 gauge needle attached to a syringe is inserted into the trigger point and local anesthetic is injected at each trigger point. Usually the dose is 1 to 5 mL of a local anesthetic (eg, 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or 0.25 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      ) at each trigger point, with or without glucocorticoid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      10 to 40 mg per trigger point) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/29,31,32\">",
"       29,31,32",
"      </a>",
"      ]. The trigger point can often be felt as a taut band under the skin or a very localized area of intense tenderness; it may twitch involuntarily when touched (called a jump sign). Most patients respond after one or two treatments, but several injections every few days to fortnightly may be needed [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/29\">",
"       29",
"      </a>",
"      ]. Dry needling, saline injection, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       botulinum toxin type A",
"      </a>",
"      injection have also been used for trigger point injections [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Local anesthetic patches &mdash; Efficacy of a 5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      patch at the area of trigger point pain has been supported by at least one placebo-controlled randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/35\">",
"       35",
"      </a>",
"      ]. The trial compared three treatments in patients with myofascial pain syndrome: a lidocaine patch applied to the trigger point for four days, a placebo patch applied to the trigger point for four days, and infiltration of the trigger point with two 1-mL injections of 0.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      hydrochloride given two days apart. The lidocaine patch was as effective as lidocaine injection, and both treatments were significantly more effective than placebo.",
"     </li>",
"     <li>",
"      Acupuncture &mdash; Direct needle insertion at the site of myofascial pain may be of some benefit. This was illustrated in a 2001 systematic analysis of twenty-three randomized and controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/36\">",
"       36",
"      </a>",
"      ]. The authors concluded that direct needling of these sites appears to be effective, but it is unclear whether the response is due to a specific or non-specific therapeutic effect. However, trials using non-penetrating sham devices, which adequately control for placebo-effects, have generated negative results, implying that most of the therapeutic response after acupuncture is due to placebo effects [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"       \"Acupuncture\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mental health issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental health issues should be addressed and managed, as appropriate, in conjunction with the treatment of any other causes of CPP that have been identified.",
"   </p>",
"   <p>",
"    Depression is common in women with CPP and warrants treatment. However, data regarding the efficacy of antidepressants in the treatment of pain in CPP are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .) The only three clinical trials that evaluated antidepressant treatment of women with CPP yielded inconclusive results. In one randomized, double-blind crossover trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    versus placebo in 23 women with CPP, sertraline did not improve the subject's pain symptoms or functional disability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/38\">",
"     38",
"    </a>",
"    ]. In the other trial, 6 of 14 women taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    reported reduction of pain; however, seven women dropped out due to side effects and one had no improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/39\">",
"     39",
"    </a>",
"    ]. An open label trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    in placebo non-responders showed improvement in depression scores, but no improvement in pain disability index scores [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of other mental health issues and disorders can be found in individual topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link\">",
"     \"Somatization: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=see_link\">",
"     \"Intimate partner violence: Intervention and patient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a prior history of pelvic inflammatory disease are at significant risk for subsequent CPP. If ongoing or subclinical infection is suspected, antibiotic treatment should be initiated. However, there is no high-quality evidence of efficacy of empiric antibiotic treatment. Antibiotic treatment regimens are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, there are no high quality clinical trials of surgical treatment for CPP after pelvic inflammatory disease. There is only anecdotal opinion regarding possible benefit of adhesiolysis, salpingectomy for hydrosalpinx, salpingo-oophorectomy for tubo-ovarian complex, or hysterectomy-salpingoophorectomy for severe adhesive disease of all reproductive viscera. In the absence of good data, such surgical approaches must be weighed carefully against the short- and long-term potential risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pelvic congestion syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although this diagnosis remains controversial, there is evidence that some women with pelvic varicosities and venous stasis, as demonstrated by pelvic venography, have associated CPP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized clinical trials suggest that medical treatment with gonadotropin-releasing hormone agonists or synthetic progestins effectively decrease pain associated with pelvic congestion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomized 84 patients to four different treatment arms: (1)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , 50 mg per day; (2) medroxyprogesterone acetate, 50 mg per day, plus psychotherapy; (3) psychotherapy plus placebo; or (4) placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/12\">",
"       12",
"      </a>",
"      ]. Women in the medroxyprogesterone acetate and psychotherapy plus medroxyprogesterone acetate groups were most likely to report significant pain relief. When treatment was stopped after four months, pain rapidly increased in the medroxyprogesterone acetate group, but recurred more slowly in the medroxyprogesterone acetate plus psychotherapy group.",
"     </li>",
"     <li>",
"      Another trial randomly assigned 47 women with venographically documented pelvic congestion to six months treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (30 mg per day) or depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      (3.6 mg per month) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/4\">",
"       4",
"      </a>",
"      ]. Both groups showed improvement in venography scores and in pelvic pain symptoms, but goserelin more effectively decreased both measures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other treatments for pelvic congestion syndrome, which have not been subjected to randomized clinical trials, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hysterectomy and bilateral salpingo-oophorectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Embolization of the ovarian veins with or without the internal iliac veins [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/44-51\">",
"       44-51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sclerotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Surgical ligation of the ovarian veins [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Efficacy of these treatments is supported only by observational data and case reports. For embolization, such studies have reported technical success rates of 89 to 97 percent and clinical success rates of 74 to 89 percent over a follow-up period of up to 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. The embolization procedure is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=see_link&amp;anchor=H6#H6\">",
"     \"Interventional radiology in management of gynecological disorders\", section on 'Pelvic congestion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adenomyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is the treatment of choice for women with significant symptoms from adenomyosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .) There is anecdotal evidence that gonadotropin-releasing hormone agonist treatment or insertion of a levonorgestrel-releasing intrauterine device may be effective treatments, but clinical studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ovarian remnant syndrome, retained ovary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment involves oophorectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link\">",
"     \"Oophorectomy and ovarian cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Leiomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal or reduction in size of leiomyomas can relieve chronic pressure symptoms. CPP is an uncommon manifestation of leiomyomas, thus treatment of these tumors for relief of chronic pain is not usually indicated. Treatment recommendations for management of uterine leiomyomas are primarily based upon outcomes described in nonrandomized, and often uncontrolled, reports. Choice of treatment modality is based upon the size and location of the leiomyomas (large versus small,",
"    <span class=\"nowrap\">",
"     submucosal/intramural/subserosal),",
"    </span>",
"    types of leiomyoma-related symptoms (bleeding, pain, pressure, infertility), age of the patient (premenopausal, perimenopausal, postmenopausal), and patient preference (side effects, cost, convenience, desire for uterine conservation versus definitive therapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Urethral diverticulum",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=see_link\">",
"     \"Urethral diverticulum in women\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Vulvar pain, dyspareunia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16249?source=see_link\">",
"     \"Treatment of vulvodynia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=see_link\">",
"     \"Differential diagnosis of sexual pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dysmenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=see_link\">",
"     \"Treatment of primary dysmenorrhea in adult women\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NONSPECIFIC TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who fail or have an inadequate response to targeted treatments, or when no specific diagnosis can be made, nonspecific treatment may be initiated, ie, directed to pain relief without regard to etiology. Such therapies may be pharmacological, surgical, psychological, or neurological (nerve blocks or neurodestructive procedures).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Heat therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat can be useful, especially for musculoskeletal pain. Heat acts as an analgesic in part by increasing blood flow and decreasing joint stiffness. It also may induce a state of mental relaxation. Superficial heating with hot packs, heating pads, or baths improves cutaneous blood flow and relaxes muscles and ligaments to a depth of 0.5 cm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with CPP have features of neuropathic pain. Neuropathic pain refers to pain due to dysfunction of the nervous system in the absence of ongoing tissue damage. The pain is characterized as sharp, shooting, or burning, and is usually felt in an area of sensory deficit. It is worsened by mild stimuli that normally would not produce pain, such as light touch or cool air. The pain tends to be chronic and causes considerable patient discomfort.",
"   </p>",
"   <p>",
"    Neuropathic pain can be treated with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , or narcotics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. One trial, which randomly assigned 56 women with CPP to gabapentin (maximum daily dose 3600 mg), amitriptyline (maximum daily dose 150 mg), or both, reported significant symptom improvement in all three groups over two years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/58\">",
"     58",
"    </a>",
"    ]. Pain relief was significantly better in patients who received gabapentin alone or in combination with amitriptyline than in those receiving amitriptyline alone. There are no large-scale randomized clinical trials of the use of these agents to treat CPP.",
"   </p>",
"   <p>",
"    The use of NSAIDs, opioids, antidepressants, anticonvulsants, and adjuvant therapies for treatment of chronic pain of any etiology is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized controlled trials evaluating the efficacy of hysterectomy in the treatment of CPP. Both prospective and retrospective cohort studies suggest that hysterectomy significantly relieves or eliminates CPP in 78 to 96 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]. A large prospective cohort study of women undergoing hysterectomy for benign conditions reported reductions in pain among women with both pain and depression preoperatively, and among women with pain only [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/62\">",
"     62",
"    </a>",
"    ]. The prevalence of pain in the two groups 24 months after surgery was 19 and 9 percent, respectively. Although fewer depressed women with pelvic pain improved after surgery than women without depression, the prevalence of pain was still significantly and substantially reduced from baseline in the group with depression.",
"   </p>",
"   <p>",
"    Supracervical hysterectomy is performed more commonly than in the past, but it is not clear if subtotal or supracervical hysterectomy is an appropriate alternative option to total hysterectomy in women with CPP. One report of 70 women who underwent supracervical hysterectomy, 31 of whom had previously been treated for endometriosis, found that 17 subsequently required removal of the cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/64\">",
"     64",
"    </a>",
"    ]. Of those 17 women, 14 had been previously treated for endometriosis associated pelvic pain. These data suggest that 45 percent of women with a history of endometriosis who are treated by subtotal hysterectomy may require subsequent removal of the cervix.",
"   </p>",
"   <p>",
"    Hysterectomy is not a good choice for the management of CPP in women who have not completed their family. Factors such as young age (less than 30 years of age) and a history of chronic pelvic inflammatory disease are associated with a relatively high chance of persistent pain symptoms following hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Nerve transection procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few high quality clinical trials examining the efficacy of nerve transection procedures for the treatment of CPP. Laparoscopic uterosacral nerve ablation (LUNA) and presacral neurectomy (PSN) are the procedures studied most intensively. Limited data suggest that LUNA is not a useful approach to the treatment of CPP, and that PSN may be modestly effective, but the success of the procedure may depend, in part, on the experience of the surgeon.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoscopic uterosacral nerve ablation &mdash; LUNA involves the destruction of the uterine nerve fibers that exit the uterus through the uterosacral ligament. Most surgeons destroy approximately 2 cm of uterosacral ligament near its attachment to the uterus.",
"     </li>",
"     <li>",
"      Presacral neurectomy &mdash; PSN refers to interruption of the sympathetic innervation of the uterus at the level of the superior hypogastric plexus. PSN is performed by incising the pelvic peritoneum over the sacrum and identifying the sacral nerve plexus, which is then transected. The right and left ureters are the lateral margins of the dissection. The procedure can be performed via laparoscopy or laparotomy. PSN is technically more challenging than LUNA because of the presence of large vessels and the ureters near the field of dissection. PSN is considered most effective for relieving midline pelvic pain, but is not thought to be as effective for relieving pelvic pain in the right and left lower quadrants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of two small randomized trials found some evidence of the effectiveness of LUNA for relief of primary dysmenorrhea at 12 months when compared to untreated controls (OR 6.12, 95% CI 1.78-21.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/66\">",
"     66",
"    </a>",
"    ]. However, the wide confidence intervals indicate that the efficacy of this surgical approach is uncertain and more data are needed. In women with endometriosis, a comparison of LUNA combined with surgical treatment of endometriosis versus surgical treatment of endometriosis alone found the addition of LUNA did not improve pain relief.",
"   </p>",
"   <p>",
"    LPSN appeared to be more effective than LUNA, although data were limited to one small randomized trial. In this trial, patients undergoing LPSN were significantly more likely to have relief of primary dysmenorrhea at 12 months than those who underwent LUNA (OR 0.10, 95% CI 0.03-0.32). In addition, PSN combined with surgical treatment of endometriosis was more effective than surgical treatment of endometriosis alone (OR 3.14, 95%CI 1.59-6.21). However, all of the procedures were performed by a single, highly experienced surgeon, which may limit the generalizability of the findings. The authors also commented that the efficacy of PSN may be specific to laparoscopic procedures and for midline abdominal pain only.",
"   </p>",
"   <p>",
"    A subsequent large randomized trial not included in the systematic review found that LUNA did not improve pain, dysmenorrhea, or dyspareunia compared with laparoscopy without pelvic denervation in patients with CPP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For both LUNA and LPSN, observational series have shown that success rates declined rapidly over time (years), possibly due to regrowth of nerves or pain signals being transferred via alternative routes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, there is evidence that LUNA is not effective in the treatment of CPP and more evidence is needed before LPSN can be recommended for treatment of CPP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Sacral nerve root neuromodulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, neuromodulation for CPP has not been well-studied. Sacral nerve root neuromodulation for bladder related symptoms and pain is the best studied technique, but all trials are observational. A review of published case series suggests a 40 to 60 percent rate of improvement in pelvic pain symptoms after placement of either unilateral or bilateral lead placement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/70\">",
"     70",
"    </a>",
"    ]. Follow-up has been up to three years in some series.",
"   </p>",
"   <p>",
"    There is some information on laparoscopic intraabdominal placement of a neuroprosthesis for CPP, but this work is still early in development and has not been widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28969/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Multidisciplinary approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although we are of the opinion that treatment in a multispecialty pain practice prior to surgery is beneficial, this has not been as well studied in CPP as in other types of chronic pain. Psychological contributors to pelvic pain and possible dependence on opiates are a major focus of most pain clinics. Pain services can develop a multimodal treatment plan that includes many of the treatments discussed above (eg, drugs, trigger point injections), as well as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychological counseling",
"     </li>",
"     <li>",
"      Acupuncture",
"     </li>",
"     <li>",
"      Behavioral and relaxation feedback therapies",
"     </li>",
"     <li>",
"      Transcutaneous electrical nerve stimulation",
"     </li>",
"     <li>",
"      Implantable nerve stimulation devices",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=see_link\">",
"       \"Patient information: Chronic pelvic pain in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=see_link\">",
"       \"Patient information: Chronic pelvic pain in women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choosing the best treatment plan for chronic pelvic pain (CPP) is based upon shared decision making by the clinician and patient. A combination of treatments may be the optimal approach. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the high frequency of endometriosis in women with a characteristic history and physical examination, we suggest empiric sequential medical treatment of these women (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Empiric trial of therapy based on diagnostic probabilities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Endometriosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although therapy specific to the patient's diagnosis might appear ideal, arriving at a diagnosis may involve costly laboratory and imaging tests, and often requires exploratory surgery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intensive diagnostic evaluation followed by targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend avoiding routine adhesiolysis in women with CPP (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Adhesiolysis may be therapeutic in a subset of patients with dense vascularized adhesions involving bowel and no other potential cause for their CPP. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adhesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of suspected endometriosis or a specific diagnosis, we initiate nonspecific treatment of chronic pain. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nonspecific treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment in a multispecialty pain practice (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Multimodal therapy (medical, surgical, and",
"      <span class=\"nowrap\">",
"       behavioral/mental",
"      </span>",
"      health therapy, along with pain consultation) is more effective than treatments that emphasize a single approach. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Multidisciplinary approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hysterectomy leads to long-term relief of CPP in many women and is an option for women who have completed childbearing. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/1\">",
"      Price J, Farmer G, Harris J, et al. Attitudes of women with chronic pelvic pain to the gynaecological consultation: a qualitative study. BJOG 2006; 113:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/2\">",
"      Lentz GM, Bavendam T, Stenchever MA, et al. Hormonal manipulation in women with chronic, cyclic irritable bladder symptoms and pelvic pain. Am J Obstet Gynecol 2002; 186:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/3\">",
"      Mathias JR, Clench MH, Reeves-Darby VG, et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig Dis Sci 1994; 39:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/4\">",
"      Soysal ME, Soysal S, Vicdan K, Ozer S. A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion. Hum Reprod 2001; 16:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/5\">",
"      Walter AJ, Hentz JG, Magtibay PM, et al. Endometriosis: correlation between histologic and visual findings at laparoscopy. Am J Obstet Gynecol 2001; 184:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/6\">",
"      Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/7\">",
"      Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/8\">",
"      Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/9\">",
"      Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/10\">",
"      Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/11\">",
"      Gambone JC, Mittman BS, Munro MG, et al. Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril 2002; 78:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/12\">",
"      Farquhar CM, Rogers V, Franks S, et al. A randomized controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion. Br J Obstet Gynaecol 1989; 96:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/13\">",
"      Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/14\">",
"      Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/15\">",
"      Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999; 93:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/16\">",
"      Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/17\">",
"      Peters AA, Trimbos-Kemper GC, Admiraal C, et al. A randomized clinical trial on the benefit of adhesiolysis in patients with intraperitoneal adhesions and chronic pelvic pain. Br J Obstet Gynaecol 1992; 99:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/18\">",
"      Kapur, BML, Rai, PC, Gulati, SM. Prevention of experimental peritoneal adhesions by low molecular weight dextran. Int Surg 1967; 48:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/19\">",
"      Haefner HK, Khoshnevisan MH, Bachman JE, et al. Use of the McGill Pain Questionnaire to compare women with vulvar pain, pelvic pain and headaches. J Reprod Med 2000; 45:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/20\">",
"      Reading AE. The internal structure of the McGill pain questionnaire in dysmenorrhoea patients. Pain 1979; 7:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/21\">",
"      Swank DJ, Swank-Bordewijk SC, Hop WC, et al. Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-centre trial. Lancet 2003; 361:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/22\">",
"      Postoperative adhesion development after operative laparoscopy: evaluation at early second-look procedures. Operative Laparoscopy Study Group. Fertil Steril 1991; 55:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/23\">",
"      Diamond MP, Daniell JF, Feste J, et al. Adhesion reformation and de novo adhesion formation after reproductive pelvic surgery. Fertil Steril 1987; 47:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/24\">",
"      Parker JD, Sinaii N, Segars JH, et al. Adhesion formation after laparoscopic excision of endometriosis and lysis of adhesions. Fertil Steril 2005; 84:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/25\">",
"      Hammoud A, Gago LA, Diamond MP. Adhesions in patients with chronic pelvic pain: a role for adhesiolysis? Fertil Steril 2004; 82:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/26\">",
"      Anderson RU, Sawyer T, Wise D, et al. Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 2009; 182:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/27\">",
"      Scott NA, Guo B, Barton PM, Gerwin RD. Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. Pain Med 2009; 10:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/28\">",
"      Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol 2001; 166:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/29\">",
"      Sharp HT. Myofascial pain syndrome of the abdominal wall for the busy clinician. Clin Obstet Gynecol 2003; 46:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/30\">",
"      FitzGerald MP, Anderson RU, Potts J, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009; 182:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/31\">",
"      Slocumb JC. Neurological factors in chronic pelvic pain: trigger points and the abdominal pelvic pain syndrome. Am J Obstet Gynecol 1984; 149:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/32\">",
"      Ling FW, Slocumb JC. Use of trigger point injections in chronic pelvic pain. Obstet Gynecol Clin North Am 1993; 20:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/33\">",
"      Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005; 118:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/34\">",
"      Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil 1994; 73:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/35\">",
"      Affaitati G, Fabrizio A, Savini A, et al. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 2009; 31:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/36\">",
"      Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: a systematic review. Arch Phys Med Rehabil 2001; 82:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/37\">",
"      Ernst E. Acupuncture--a critical analysis. J Intern Med 2006; 259:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/38\">",
"      Engel CC Jr, Walker EA, Engel AL, et al. A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain. J Psychosom Res 1998; 44:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/39\">",
"      Walker EA, Roy-Byrne PP, Katon WJ, Jemelka R. An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med 1991; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/40\">",
"      Brown CS, Franks AS, Wan J, Ling FW. Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. J Reprod Med 2008; 53:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/41\">",
"      Beard RW, Highman JH, Pearce S, Reginald PW. Diagnosis of pelvic varicosities in women with chronic pelvic pain. Lancet 1984; 2:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/42\">",
"      Reginald PW, Beard RW, Kooner JS, et al. Intravenous dihydroergotamine to relieve pelvic congestion with pain in young women. Lancet 1987; 2:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/43\">",
"      Beard RW, Kennedy RG, Gangar KF, et al. Bilateral oophorectomy and hysterectomy in the treatment of intractable pelvic pain associated with pelvic congestion. Br J Obstet Gynaecol 1991; 98:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/44\">",
"      Pieri S, Agresti P, Morucci M, de' Medici L. Percutaneous treatment of pelvic congestion syndrome. Radiol Med 2003; 105:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/45\">",
"      Venbrux AC, Chang AH, Kim HS, et al. Pelvic congestion syndrome (pelvic venous incompetence): impact of ovarian and internal iliac vein embolotherapy on menstrual cycle and chronic pelvic pain. J Vasc Interv Radiol 2002; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/46\">",
"      Chung MH, Huh CY. Comparison of treatments for pelvic congestion syndrome. Tohoku J Exp Med 2003; 201:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/47\">",
"      Cordts PR, Eclavea A, Buckley PJ, et al. Pelvic congestion syndrome: early clinical results after transcatheter ovarian vein embolization. J Vasc Surg 1998; 28:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/48\">",
"      Sichlau MJ, Yao JS, Vogelzang RL. Transcatheter embolotherapy for the treatment of pelvic congestion syndrome. Obstet Gynecol 1994; 83:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/49\">",
"      Kwon SH, Oh JH, Ko KR, et al. Transcatheter ovarian vein embolization using coils for the treatment of pelvic congestion syndrome. Cardiovasc Intervent Radiol 2007; 30:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/50\">",
"      Kim HS, Malhotra AD, Rowe PC, et al. Embolotherapy for pelvic congestion syndrome: long-term results. J Vasc Interv Radiol 2006; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/51\">",
"      d'Archambeau O, Maes M, De Schepper AM. The pelvic congestion syndrome: role of the \"nutcracker phenomenon\" and results of endovascular treatment. JBR-BTR 2004; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/52\">",
"      Ghosh A, Shafie-Pour H, Ayers KJ. Laparoscopic sclerotherapy in a case of pelvic congestion syndrome. BJOG 2006; 113:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/53\">",
"      Tropeano G, Di Stasi C, Amoroso S, et al. Ovarian vein incompetence: a potential cause of chronic pelvic pain in women. Eur J Obstet Gynecol Reprod Biol 2008; 139:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/54\">",
"      Gargiulo T, Mais V, Brokaj L, et al. Bilateral laparoscopic transperitoneal ligation of ovarian veins for treatment of pelvic congestion syndrome. J Am Assoc Gynecol Laparosc 2003; 10:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/55\">",
"      Belenky A, Bartal G, Atar E, et al. Ovarian varices in healthy female kidney donors: incidence, morbidity, and clinical outcome. AJR Am J Roentgenol 2002; 179:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/56\">",
"      Chavez NF, Zweizig SL, Stewart EA. Neuropathic uterine pain after hysterectomy. A case report. J Reprod Med 2003; 48:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/57\">",
"      Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005; 293:3043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/58\">",
"      Sator-Katzenschlager SM, Scharbert G, Kress HG, et al. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr 2005; 117:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/59\">",
"      Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994; 83:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/60\">",
"      Tay SK, Bromwich N. Outcome of hysterectomy for pelvic pain in premenopausal women. Aust N Z J Obstet Gynaecol 1998; 38:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/61\">",
"      Stovall TG, Ling FW, Crawford DA. Hysterectomy for chronic pelvic pain of presumed uterine etiology. Obstet Gynecol 1990; 75:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/62\">",
"      Hartmann KE, Ma C, Lamvu GM, et al. Quality of life and sexual function after hysterectomy in women with preoperative pain and depression. Obstet Gynecol 2004; 104:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/63\">",
"      Brandsborg B, Nikolajsen L, Hansen CT, et al. Risk factors for chronic pain after hysterectomy: a nationwide questionnaire and database study. Anesthesiology 2007; 106:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/64\">",
"      Okaro EO, Jones KD, Sutton C. Long term outcome following laparoscopic supracervical hysterectomy. BJOG 2001; 108:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/65\">",
"      Hillis SD, Marchbanks PA, Peterson HB. The effectiveness of hysterectomy for chronic pelvic pain. Obstet Gynecol 1995; 86:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/66\">",
"      Proctor ML, Latthe PM, Farquhar CM, et al. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2005; :CD001896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/67\">",
"      Daniels J, Gray R, Hills RK, et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA 2009; 302:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/68\">",
"      Chen FP, Chang SD, Chu KK, Soong YK. Comparison of laparoscopic presacral neurectomy and laparoscopic uterine nerve ablation for primary dysmenorrhea. J Reprod Med 1996; 41:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/69\">",
"      Papasakelariou, C. Long-term results of laparoscopic uterosacral nerve ablation. Gynaecological Endoscopy 1996; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/70\">",
"      Mayer RD, Howard FM. Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain. Neurotherapeutics 2008; 5:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/71\">",
"      Possover M. Laparoscopic management of neural pelvic pain in women secondary to pelvic surgery. Fertil Steril 2009; 91:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28969/abstract/72\">",
"      Possover M, Baekelandt J, Chiantera V. The laparoscopic approach to control intractable pelvic neuralgia: from laparoscopic pelvic neurosurgery to the LION procedure. Clin J Pain 2007; 23:821.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5435 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28969=[""].join("\n");
var outline_f28_18_28969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Empiric trial of therapy based on diagnostic probabilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intensive diagnostic evaluation followed by targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonspecific analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EMPIRIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TARGETED TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interstitial cystitis/painful bladder syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Myofascial pain syndrome (trigger point pain)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mental health issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pelvic congestion syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ovarian remnant syndrome, retained ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Urethral diverticulum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Vulvar pain, dyspareunia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NONSPECIFIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Heat therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Nerve transection procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Sacral nerve root neuromodulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Multidisciplinary approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5435|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/49/4893\" title=\"table 1\">",
"      Causes of CPP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/5/40027\" title=\"table 2A\">",
"      ACOG CPP Rx A recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/62/5100\" title=\"table 2B\">",
"      ACOG CPP Rx BC recs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40389?source=related_link\">",
"      Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=related_link\">",
"      Differential diagnosis of sexual pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=related_link\">",
"      Evaluation of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=related_link\">",
"      Intimate partner violence: Intervention and patient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=related_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33127?source=related_link\">",
"      Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=related_link\">",
"      Somatization: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=related_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=related_link\">",
"      Treatment of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16249?source=related_link\">",
"      Treatment of vulvodynia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=related_link\">",
"      Urethral diverticulum in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_18_28970="Treatment and prevention of invasive aspergillosis";
var content_f28_18_28970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of invasive aspergillosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28970/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28970/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/18/28970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/18/28970/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/18/28970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus species are ubiquitous and exposure to their spores is frequent, but invasive aspergillosis is uncommon and occurs primarily in immunocompromised hosts. Neutropenia and glucocorticoid use are the most common predisposing factors. The infecting species is most commonly A. fumigatus, but other species, including A. flavus, A. terreus, and A. niger, also cause disease. The effective management of invasive aspergillosis includes strategies to optimize prevention and early antifungal treatment, immunomodulation, and, in some cases, the role of surgery.",
"   </p>",
"   <p>",
"    The treatment and prevention of invasive aspergillosis will be reviewed here. The clinical features and diagnosis of invasive aspergillosis are discussed separately; treatment of the other manifestations of Aspergillus infection is also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35270?source=see_link\">",
"     \"Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11178?source=see_link\">",
"     \"Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=see_link\">",
"     \"Treatment of chronic pulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology and prophylaxis of invasive fungal infections in patients with hematologic malignancies and hematopoietic cell transplant recipients are also discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5048311\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America (IDSA) released updated guidelines for the treatment of invasive aspergillosis in 2008. Our recommendations are in keeping with the IDSA guidelines. The American Thoracic Society (ATS) published guidelines for treatment of fungal infections in adult pulmonary and critical care patients in 2011; the ATS recommendations for the management of invasive aspergillosis are generally similar to those of the IDSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three classes of antifungal agents are available for the treatment of aspergillosis: polyenes, azoles, and echinocandins. Historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate was the major antifungal drug used in patients with invasive aspergillosis. Currently, the drug of choice for invasive aspergillosis is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2-9\">",
"     2-9",
"    </a>",
"    ]. Lipid formulations of amphotericin B are also used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/10\">",
"     10",
"    </a>",
"    ]. Echinocandins have activity against Aspergillus spp, but have a limited role because they have not been studied adequately for initial treatment of invasive aspergillosis.",
"   </p>",
"   <p>",
"    The appropriate initial antifungal depends upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the diagnosis of invasive aspergillosis has been established, the drug of choice is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/3,9\">",
"       3,9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Voriconazole'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients who are intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (Abelcet or AmBisome) is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lipid formulations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If an invasive mold infection is suspected, but the diagnosis of invasive aspergillosis has not been established, particularly in those who have recently received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , one should consider treating empirically with a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in order to provide antifungal activity against both aspergillosis and mucormycosis, since the Mucorales are intrinsically resistant to voriconazole. Breakthrough mucormycosis infections have been reported in transplant patients receiving voriconazole [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. When the diagnosis is uncertain, it should be pursued aggressively even after empiric therapy has been initiated. If the diagnosis of aspergillosis is established, the patient should be switched to voriconazole. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"       \"Diagnosis of invasive aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is important to note that some drugs, especially azoles, interact with chemotherapy used in conditioning regimens, potentially increasing toxicities (eg, neurotoxicity from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ), or reducing the efficacy of certain cytotoxic drugs. Hence, it is wise to initiate these agents subsequent to cytotoxic therapies,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      administer a non-interacting mold-active antifungal during conditioning chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific interactions of azole agents with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions. An overview of the drug interactions associated with the azoles is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34483456\">",
"    <span class=\"h3\">",
"     Outbreak of fungal meningitis and septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients affected by the 2012 United States outbreak of fungal meningitis and septic arthritis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19321?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Triazoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triazole antifungal agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Fluconazole has no activity against Aspergillus spp, and itraconazole has become a second-line agent for aspergillosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is the drug of choice for invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2-8\">",
"     2-8",
"    </a>",
"    ], and was recommended in the 2008 Infectious Diseases Society of America guidelines on the treatment of aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best efficacy data come from an international, multicenter randomized open-label trial in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate as initial therapy in 277 patients with confirmed or probable invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with multiple underlying diseases were enrolled, although the majority had hematologic malignancies and many had undergone hematopoietic cell transplantation. Primary therapy with voriconazole (administered at 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV twice a day on day 1, followed by 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily for at least seven days, with the option to switch to oral dosing at 200 mg orally twice daily thereafter) was compared with amphotericin B deoxycholate (1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily). The treating clinician had the opportunity to switch the patient to another antifungal agent for drug intolerance or clinical failure. Most of the changes in therapy were in the amphotericin B deoxycholate arm; patients were most often switched to a lipid formulation of amphotericin B because of intolerance.",
"   </p>",
"   <p>",
"    The following significant benefits were noted in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    group compared with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate group at 12 weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater likelihood of a complete or partial response (53 versus 32 percent).",
"     </li>",
"     <li>",
"      A lower mortality rate (29 versus 42 percent).",
"     </li>",
"     <li>",
"      A lesser likelihood of the clinician changing the patient to another antifungal agent because of intolerance or poor response (36 versus 80 percent).",
"     </li>",
"     <li>",
"      A lower rate of severe adverse reactions, although 45 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      reported transient visual disturbances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate in patients with invasive aspergillosis.",
"    <strong>",
"    </strong>",
"    The relative efficacy of voriconazole compared with a lipid formulation of amphotericin B is unknown since no comparative studies have been published.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    may also have a role in the setting of central nervous system disease, for which the mortality rate historically has approached 100 percent. In a retrospective study of 48 patients with definite and 33 patients with probable central nervous system aspergillosis, 31 percent of patients who received voriconazole survived for a median observation time of 390 days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/13\">",
"     13",
"    </a>",
"    ]. The vast majority of patients had received antifungal agents other than voriconazole for a median of 31 days prior to receiving voriconazole.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is available in both intravenous and oral formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/9,11,13\">",
"     9,11,13",
"    </a>",
"    ]. The recommended dosing regimen is 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV twice a day on day 1 followed by 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV twice daily. When the patient is able to take oral medications, one can consider switching to the oral form. Optimal oral dosing is a matter of controversy. The currently recommended dose of 200 mg twice daily has been noted to result in low or even unmeasurable serum concentrations in a substantial proportion of patients, and high concentrations may be associated with excessive toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/14\">",
"     14",
"    </a>",
"    ]. The dose of oral voriconazole can be increased to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily (or 300 mg orally twice daily) in patients who have disease progression. We suggest monitoring serum voriconazole trough concentrations in all patients receiving voriconazole for invasive aspergillosis. Although there are no guidelines for target voriconazole concentrations, we suggest checking a trough concentration one week into therapy with a goal range of &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and &lt;5.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/14\">",
"     14",
"    </a>",
"    ]. Trough concentrations below 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    warrant an increase in the voriconazole dose and appropriate subsequent monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/15\">",
"     15",
"    </a>",
"    ]. On the other hand, serum drug concentrations above 5.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    warrant a reduction in the voriconazole dose, because they have been associated with an increased risk of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with invasive aspergillosis caused by A. fumigatus who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , antifungal resistance should be considered. (See",
"    <a class=\"local\" href=\"#H458851271\">",
"     'Antifungal resistance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link&amp;anchor=H5#H5\">",
"     \"Mucormycosis (zygomycosis)\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is associated with a number of drug interactions, which the clinician should carefully check for when prescribing this medication. The drug has also been reported to cause visual changes, hallucinations, and a photosensitivity skin rash. Studies suggest that people who receive this drug for long periods may have an increased risk for skin cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H16#H16\">",
"     \"Pharmacology of azoles\", section on 'Voriconazole'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     \"Voriconazole: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is a broad-spectrum triazole that has been approved by the US Food and Drug Administration for prophylaxis of fungal infections in neutropenic patients and for the treatment of mucocutaneous candidiasis. It is similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in its activity against Aspergillus species [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], but little has been published to date on its efficacy for the primary treatment of invasive aspergillosis.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    as monotherapy was investigated in an open-label, multicenter trial in patients with invasive aspergillosis and other mycoses who were refractory to or intolerant of conventional antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/20\">",
"     20",
"    </a>",
"    ]. Data from external control cases were collected retrospectively as a comparative reference group. The overall success rate was 42 percent for 107 posaconazole recipients and 26 percent for 86 controls. The differences in treatment outcomes were maintained across several prespecified patient subsets (eg, site of infection, underlying disease, and indication for enrollment, refractory disease versus intolerance of therapy).",
"   </p>",
"   <p>",
"    Given its spectrum of activity and the treatment success observed in the uncontrolled trial described above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    may be an effective agent for the treatment of invasive aspergillosis. However, further study is necessary before it can be recommended for initial therapy of invasive aspergillosis. The most common side effect of posaconazole is gastrointestinal upset [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/21\">",
"     21",
"    </a>",
"    ]. Effective absorption of the drug requires oral intake, optimally with a high-fat meal; absorption may be impaired in the setting of gastrointestinal tract disruption (eg, graft-versus-host disease or mucositis) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H9#H9\">",
"     \"Pharmacology of azoles\", section on 'Posaconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is considered a second-line agent for the treatment of aspergillosis and is rarely used in immunocompromised patients with invasive disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has greater intrinsic activity against Aspergillus species, and both the intravenous and the oral formulations are better tolerated than those of itraconazole.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    has been used in selected patients with mild immunosuppression and non-life-threatening Aspergillus infection or in patients who had already been stabilized with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . In a multicenter, open-label study of 76 evaluable patients who were treated with itraconazole, only 39 percent had a complete or partial response [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/23\">",
"     23",
"    </a>",
"    ]. Other drawbacks associated with use of itraconazole include the requirement of an acid environment for absorption, poor bioavailability, and important drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used for the treatment of aspergillosis, the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    concentration should be measured two weeks into therapy. If there is a change in clinical condition, serum concentrations of itraconazole should be rechecked. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Amphotericin B deoxycholate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate has been available for the longest period of time, we have the most extensive experience with this drug for treating aspergillosis. However, administration of amphotericin B deoxycholate is associated with severe nephrotoxicity, and treatment outcomes have been poor. Less toxic options, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or a lipid formulation of amphotericin B, should be used in patients with aspergillosis when available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lipid formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three currently marketed lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       Amphotericin B lipid complex",
"      </a>",
"      (ABLC, Abelcet)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       Liposomal amphotericin B",
"      </a>",
"      (AmBisome)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/57/26518?source=see_link\">",
"       Amphotericin B cholesteryl sulfate complex",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      colloidal dispersion, ABCD, Amphotec)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main advantage of the lipid formulations is the ability to administer larger doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    with fewer toxicities.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     Amphotericin B lipid complex",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    have fewer infusion-related side effects than amphotericin B deoxycholate, but ABCD has similar rates of infusion reactions as amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/24\">",
"     24",
"    </a>",
"    ]. The lipid formulations, although less toxic, have not been definitively shown to result in better outcomes compared to conventional amphotericin B. One randomized trial showed that ABCD was not superior to amphotericin B deoxycholate in treating aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the treatment of invasive aspergillosis, the recommended initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day, and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    is 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/3\">",
"     3",
"    </a>",
"    ]. A small observational study suggested that using higher doses of lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    results in better response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/26\">",
"     26",
"    </a>",
"    ]. However, a double-blind trial in 201 patients with confirmed aspergillosis compared the efficacy of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day versus 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day dosing for the first 14 days of treatment, followed by receipt of 3",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/10\">",
"     10",
"    </a>",
"    ]. The vast majority of patients had underlying hematologic malignancies and neutropenia. Patients assigned to the higher dosing arm had a higher rate of nephrotoxicity without any additional clinical benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    , an echinocandin, has been approved by the US FDA for the treatment of invasive aspergillosis in patients who cannot tolerate or who are refractory to standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/27\">",
"     27",
"    </a>",
"    ]. It is not utilized for primary therapy of invasive aspergillosis because of a lack of data in this setting; it is used for salvage therapy, often in combination with another antifungal drug [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Combination therapy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    In a compassionate salvage treatment trial for proven or probable invasive aspergillosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    was administered to 83 patients who were intolerant of standard therapy (15 percent of patients) or whose infection was refractory to standard therapy (85 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/32\">",
"     32",
"    </a>",
"    ]. Almost all had previously received an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation. The overall complete and partial success rate was 45 percent; as expected, the response rates were higher for the patients who were intolerant of standard therapy compared to those who were refractory (75 versus 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    administration requires an intravenous loading dose of 70 mg, followed by 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    once daily. Caspofungin is well tolerated and has few drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=see_link\">",
"     \"Pharmacology of echinocandins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other echinocandins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , are not FDA-approved for the treatment of invasive aspergillosis. However, these agents have activity against Aspergillus spp, and in many hospitals all three echinocandins are considered to have equivalent efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458851271\">",
"    <span class=\"h2\">",
"     Antifungal resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some species of Aspergillus are known to have variable susceptibilities to different antifungal drugs. Aspergillus terreus is less susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in vitro and in animal models, and clinical reports suggest that outcomes are better with use of alternative drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some species, such as A. ustus, A. lentulus, and Neosartorya udagawae, that have been recognized recently to cause disease generally exhibit relatively high level resistance to multiple antifungal agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    . The clinical significance of this relative resistance is not well defined, although case series suggest poor outcomes in patients with documented infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although in vitro resistance among Aspergillus spp has been rare to date, isolates of A. fumigatus that exhibit relative cross-resistance to multiple azoles have been reported and may be increasing in prevalence in certain countries in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Surveillance in the Netherlands revealed the emergence in 2000 of a set of mutations in A. fumigatus isolates that confers reduced susceptibility to azoles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/38\">",
"     38",
"    </a>",
"    ]. An amino acid substitution of leucine for histidine at codon 98, in conjunction with a tandem repeat in the gene promoter, causes resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and increased minimum inhibitory concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    . Among isolates in the surveillance study in the Netherlands (which included several isolates from other countries in Europe), the annual prevalence between 2000 and 2007 ranged from 1.7 to 6 percent. A. fumigatus isolates possessing these mutations have been cultured from patients with invasive aspergillosis involving the lungs, central nervous system, sinuses, and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination antifungal therapy has been evaluated primarily in patients who have not responded to their initial regimen. However, the role of combination antifungal therapy as either initial or salvage therapy is unproven, since a possible increase in efficacy must be weighed against a possible increase in toxicity and potential antagonistic effects of the drug combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For salvage therapy in patients who do not respond to monotherapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , we suggest the use of a combination antifungal regimen. We suggest adding an echinocandin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , to voriconazole or to liposomal amphotericin",
"    <strong>",
"    </strong>",
"    B. There are no clinical data to support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    with triazoles for combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617537\">",
"    <span class=\"h3\">",
"     Voriconazole and caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental models of aspergillosis have suggested benefit of a variety of antifungal combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The following observations illustrate the range of findings in clinical studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated 47 patients with evidence of progressive infection after seven or more days of treatment with an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      preparation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/30\">",
"       30",
"      </a>",
"      ]. Thirty-one patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      alone; the next 16 patients were given voriconazole plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      . Using a multivariate model, at three months, patients who received combination therapy had a significantly lower rate of mortality (odds ratio 0.28) compared with those who received voriconazole monotherapy.",
"     </li>",
"     <li>",
"      In a retrospective analysis of 405 hematopoietic cell transplant recipients with probable or proven aspergillosis, there was no difference in clinical outcomes in the 33 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      as primary antifungal therapy compared with those who were treated with voriconazole monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, 40 solid organ transplant patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      as primary therapy were compared with a historical control group of 47 patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/46\">",
"       46",
"      </a>",
"      ]. Combination therapy was associated with reduced mortality in the subset of patients with A. fumigatus infection (adjusted hazard ration [HR] 0.37, 95% CI 0.16-0.84) and in those with renal failure (adjusted HR 0.32, 95% CI 0.12-0.85).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the suggestion of benefit of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    in some studies, there are major limitations that must be considered. Historical controls are of limited utility because improvements in early diagnosis and therapy of the underlying condition will impact outcomes in the cohort treated during a later time period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clinical trial comparing the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    to voriconazole monotherapy for invasive aspergillosis is currently underway [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Liposomal amphotericin B and caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , there was substantial interest in combination regimens of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (AmBisome) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    for invasive aspergillosis. This combination has shown some benefit compared with liposomal amphotericin monotherapy, but has not been compared with voriconazole monotherapy.",
"   </p>",
"   <p>",
"    In a small prospective open-label study of 30 patients with hematologic malignancies with probable or, in a few cases, proven invasive aspergillosis, a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    was compared with monotherapy with high-dose liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) for initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/48\">",
"     48",
"    </a>",
"    ]. There were significantly more favorable responses (partial or complete) in the combination therapy group (10 of 15 patients versus 4 of 15 patients with liposomal amphotericin B). At 12 weeks, survival rates were 100 percent in the combination therapy group compared with 80 percent in the amphotericin B monotherapy group.",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    has also been studied in small retrospective studies as a salvage regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. One of these studies evaluated 48 patients with hematologic malignancy and invasive aspergillosis (23 probable, 25 possible); in two-thirds of patients, caspofungin was added after failure to respond to at least seven days of liposomal amphotericin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/29\">",
"     29",
"    </a>",
"    ]. Only 18 percent of these patients responded to combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Amphotericin B and triazoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical data to support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    with a triazole for combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Animal models of aspergillosis suggest that triazoles may be antagonistic when given concomitantly or sequentially with amphotericin B [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. One proposed mechanism to explain these observations includes the reduction of amphotericin B binding to fungal membranes due to azole inhibition of the ergosterol biosynthetic pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/50\">",
"     50",
"    </a>",
"    ]. An alternative mechanism may be the accumulation of azole in the cell membrane, which competitively inhibits the binding of amphotericin B to ergosterol.",
"   </p>",
"   <p>",
"    Differences in treatment outcomes with polyenes and triazoles may also be specific to the combination used. As an example, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    has significantly more synergistic activity in vitro against Aspergillus hyphae than the combination of amphotericin B and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/53\">",
"     53",
"    </a>",
"    ]. Why this occurs is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in the treatment of invasive aspergillosis has not been shown to be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617627\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antifungal therapy is dependent upon the location of the infection, the patient's underlying disease, the need for further immunosuppression, and the response to therapy. Antifungal therapy is generally continued until all signs and symptoms of the infection have resolved and often longer in patients with persistent immune defects. Radiographic abnormalities should have stabilized and signs of active infection should have disappeared before treatment is discontinued. For most immunosuppressed patients, antifungal therapy will continue for months or even years in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H834005\">",
"    <span class=\"h2\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who complete antifungal therapy are at risk for reactivation of aspergillosis if neutropenia recurs. Individuals who are at high risk of relapse, such as those who receive chemotherapy or hematopoietic cell transplantation, require secondary prophylaxis. (See",
"    <a class=\"local\" href=\"#H833930\">",
"     'Secondary prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pathogenesis of relapsed invasive aspergillosis is thought to be due to reactivation of a latent, subclinical infection that had not been fully eradicated. This may be secondary to the angioinvasive nature of the organism or due to lack of sterilization secondary to poor drug penetration (eg, foreign bodies, vegetations, or lung or bone sequestra) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/54\">",
"     54",
"    </a>",
"    ]. Factors that predispose patients to relapsing invasive aspergillosis include site of infection (eg, sinuses), use of systemic glucocorticoids, lack of remission of underlying hematologic malignancy, duration of neutropenia, and receipt of an unrelated hematopoietic stem cell transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/54\">",
"     54",
"    </a>",
"    ]. The recognition that certain variations in innate immunity increase the risk of invasive aspergillosis suggest that at least some of these infections may represent reinfection due to ongoing high risk of disease; examples include polymorphisms in the genes encoding toll-like receptor-4, dectin-1, and mannose-binding lectin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458851100\">",
"    <span class=\"h1\">",
"     IMMUNOMODULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive aspergillosis occurs most commonly in the setting of immunosuppression, particularly chemotherapy-induced neutropenia or glucocorticoid administration for graft-versus-host disease (GVHD). In neutropenic patients, recovery of bone marrow function is critical to the control of aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/54\">",
"     54",
"    </a>",
"    ]; in the hematopoietic cell transplant recipient with aspergillosis, for example, failure to engraft will result in death due to this infection. Whenever possible, the degree of immunosuppression should be decreased as an adjunct to antifungal therapy for the treatment of invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high mortality observed in invasive aspergillosis reflects the influence of the underlying disease on outcome and the frequent inability to improve immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/55\">",
"     55",
"    </a>",
"    ]. The importance of the degree of immunosuppression on outcome was illustrated in an international multicenter retrospective series of 525 patients with invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/3\">",
"     3",
"    </a>",
"    ]. Complete or partial responses to therapy occurred in significantly fewer patients with severe immunosuppression compared to those with less marked immunosuppression (28 versus 51 percent). In a detailed review of 400 patients who had aspergillosis in the setting of hematopoietic cell transplantation or treatment of hematologic malignancy, the most important prognostic factors included clinical variables that dictated overall immune impairment (GVHD severity and HLA mismatch), relative paucity of multiple cell types (neutropenia, monocytopenia, and lymphocytopenia), as well as kidney and liver impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These outcomes studies demonstrate the complexity of caring for patients with invasive aspergillosis; the worst outcomes occur in patients with persistent, severe immune dysfunction, and in those with organ impairment that limits administration of antifungals. Although the relative contribution of these prognostic indicators is unclear, it is generally accepted that decreasing immune suppression will result in improved outcomes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458851107\">",
"    <span class=\"h2\">",
"     Colony-stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colony-stimulating growth factors enhance neutrophil chemotaxis and phagocytosis and attract neutrophils to the site of inflammation. In clinical studies, G-CSF shortens the period of neutropenia following myelosuppressive chemotherapy, leading to shorter hospitalizations, fewer documented infections, and fewer days of antimicrobial therapy.",
"   </p>",
"   <p>",
"    Despite these positive effects, there is currently no definitive proof that hematopoietic growth factors decrease mortality from infection, improve the response rate to antibiotics, or improve overall survival. Furthermore, there is no evidence to support the role of colony-stimulating factors to increase innate neutrophil fungicidal capacity. An in vitro study examined the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) and interferon-gamma to increase neutrophil oxidative burst and damage Aspergillus hyphae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/56\">",
"     56",
"    </a>",
"    ]. Both cytokines increased oxidative burst: G-CSF by 37 percent and interferon-gamma by 71 percent. Damage to hyphae by neutrophils was also increased by both cytokines whether or not the hyphae were opsonized; combination of the two cytokines produced an additive effect.",
"   </p>",
"   <p>",
"    The clinical significance of these observations is uncertain. At present, we do not recommend routine use of colony-stimulating factors in neutropenic patients with invasive aspergillosis. Consideration of the risks and benefits should be made on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458851114\">",
"    <span class=\"h2\">",
"     Granulocyte infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data to support the use of donor granulocyte infusions for the management of patients with neutropenia and invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/57\">",
"     57",
"    </a>",
"    ]. Experience has been limited to situations in which severe disease warranted drastic measures. A randomized trial is underway regarding the potential utility of G-CSF-stimulated community donor granulocyte transfusions for infection that develops in the setting of neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ROLE OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery can be used to debride necrotic tissue and to remove infected tissue in patients with invasive aspergillosis. The decision of whether to perform surgery depends on many factors, including the extent and location of the lesion(s), the degree of resection required, comorbidities, the ability of the patient to tolerate surgery, the potential impact of delay of chemotherapy, and the overall goals of antineoplastic therapy (eg, curative versus palliative) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/3\">",
"     3",
"    </a>",
"    ]. Many neutropenic patients have profound thrombocytopenia, which may complicate or preclude surgery as a therapeutic option. Debridement is essential for the treatment of Aspergillus rhinosinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/58\">",
"     58",
"    </a>",
"    ]. Radical surgical debridement is required in many cases to achieve cure, and sometimes requires multiple surgeries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link&amp;anchor=H4#H4\">",
"     \"Fungal rhinosinusitis\", section on 'Invasive fungal sinusitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery may be indicated for settings in which a large degree of necrosis limits antifungal activity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is an imminent threat to vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/1\">",
"     1",
"    </a>",
"    ]. Examples include: endocarditis, extensive necrotic cutaneous lesions, pericardial infection, empyema, invasion of the chest wall from a contiguous pulmonary lesion, pulmonary lesions in proximity to great vessels or pericardium, infected prosthetic devices, and osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mortality benefit to surgery for the management of cerebral lesions in combination with antifungal therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has been suggested in small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/13\">",
"     13",
"    </a>",
"    ]. However, with current antifungal management many patients resolve residual central nervous system disease without need for surgical management. &nbsp;",
"   </p>",
"   <p>",
"    Surgical excision of a pulmonary cavity has been performed in patients with a single pulmonary lesion and recurrent hemoptysis or bacterial superinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/59\">",
"     59",
"    </a>",
"    ]. As an example, one retrospective series evaluated 41 patients with hematologic disease complicated by neutropenia and invasive pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients underwent lobectomy (23 patients), wedge resection (16 patients) or enucleation of a mass lesion (two patients); complication rate and 30-day mortality were both estimated to be 10 percent. Outcomes were generally good (response rate 80 percent), and were associated with successful treatment of the underlying hematologic malignancy. In this study, it was not possible to identify which patients benefit most from a surgical approach. Although the authors were in favor of a combined medical and surgical approach, our experience has been that most patients with hematologic malignancies do not require surgery. We recommend initial medical therapy with sequential follow-up to determine whether surgery is necessary, except in cases of impending major bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833547\">",
"    <span class=\"h1\">",
"     PREVENTION AND EARLY TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies performed in the 1990s and early 2000s reported very poor outcomes for invasive aspergillosis. Mortality rates ranged from 60 to 90 percent, and were largely dependent upon the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/61\">",
"     61",
"    </a>",
"    ]. Overall survival has improved, but varies depending upon factors such as duration of neutropenia, dosage of glucocorticoids, liver and kidney function, and site and extent of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2,62\">",
"     2,62",
"    </a>",
"    ]. A great deal of effort has been put into preventing infections by utilizing prophylactic strategies, and into treating invasive aspergillosis as early as possible by either empiric treatment of febrile patients with neutropenia or preemptive treatment based upon results of screening assays for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues are briefly reviewed here; more extensive discussions are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974350#H154974350\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Addition of an antifungal agent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link&amp;anchor=H8#H8\">",
"     \"Prophylaxis of infections in solid organ transplantation\", section on 'Antifungal prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H23#H23\">",
"     \"Fungal infections following lung transplantation\", section on 'Invasive fungal infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833572\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providing prophylaxis with mold-active drugs can prevent invasive aspergillosis. Results of several randomized trials are summarized as follows: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      was more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      for preventing aspergillosis in patients receiving therapy for acute myeloid leukemia (absolute reduction in the posaconazole group, -6%, 95% CI -9.7 to -2.5%) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/65\">",
"       65",
"      </a>",
"      ], and more effective than fluconazole in allogeneic hematopoietic cell transplant recipients with severe graft-versus-host disease (odds ratio [OR] 0.31, 95% CI 0.13 to 0.75) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      was associated with fewer cases of documented infections caused by Aspergillus species compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (both with galactomannan antigen monitoring), although these results failed to reach statistical superiority in a study endpoint that included measurement of survival [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      may be more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      in preventing aspergillosis in patients with leukemia and in hematopoietic cell transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/68-70\">",
"       68-70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhaled administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulations reduced the incidence of aspergillosis in patients with hematologic malignancies who had prolonged neutropenia (OR 0.26, 95% CI 0.09-0.72) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Based upon observational data, inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      is often used in lung transplant recipients during the early post-transplant period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H24#H24\">",
"       \"Fungal infections following lung transplantation\", section on 'Nebulized amphotericin B'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive results from each of these studies are balanced with the potential drawbacks of prophylaxis, including possible toxicities and drug interactions, costs of the drugs, and the potential generation of microbial resistance. Oral drugs often are poorly absorbed in the setting of gastrointestinal tract mucositis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/22\">",
"     22",
"    </a>",
"    ]. Which specific patients will benefit from prophylactic strategies remains ill-defined and is partly dependent upon patient characteristics and the epidemiology of invasive fungal infections at individual institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833579\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy involves antifungal treatment of febrile patients during periods of neutropenia. This strategy was first introduced as a means to prevent invasive fungal infections in the 1980s after it was noted that many patients with fevers had underlying, otherwise undiagnosed, fungal infections, particularly invasive candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/72\">",
"     72",
"    </a>",
"    ]. Such infections were especially common in patients with a long duration of neutropenia who were not receiving azole prophylaxis.",
"   </p>",
"   <p>",
"    Empiric antifungal treatment after a defined duration of persistent fever has become standard practice, and multiple drugs have been studied and approved for this indication. It is important to note that placebo-controlled trials have not been performed to prove the benefit in the era of widespread azole prophylaxis, and the drugs have potential negative effects (eg, toxicity, cost). This subject is reviewed in more depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974350#H154974350\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Addition of an antifungal agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833586\">",
"    <span class=\"h2\">",
"     Preemptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive therapy is an early treatment strategy that has been proposed as an alternative to empiric therapy. Preemptive therapy involves initiating antifungal therapy based upon the results of serial screening for aspergillosis. Randomized trials are currently being performed to assess this approach. Results of studies that have compared preemptive therapy to empiric therapy have shown:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No overall clinical or survival benefit to a preemptive strategy that involved serial polymerase chain reaction testing in patients with hematologic malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No survival benefit of a preemptive strategy that used the serum galactomannan assay in combination with other clinical indicators in patients with hematologic malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/74\">",
"       74",
"      </a>",
"      ]. Probable or proven invasive fungal infections were significantly more common among those who received preemptive therapy (9 versus 4 percent), but some of these infections were due to Candida spp rather than molds. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486430#H1064486430\">",
"       \"Diagnosis of invasive aspergillosis\", section on 'Galactomannan antigen detection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the results of these studies suggest limited benefit of a preemptive strategy, neither of the trials provides definitive conclusions due to study design issues. Since the safety and efficacy of replacing empiric therapy with preemptive therapy in neutropenic patients has not been established, the latter approach cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833930\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prophylaxis involves the reinitiation of antifungal therapy during periods of increased risk of relapse, such as following chemotherapy or hematopoietic cell transplantation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has been evaluated as secondary prophylaxis to prevent relapsed aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/75\">",
"     75",
"    </a>",
"    ]. In patients at increased risk of relapse following the completion of primary treatment, we recommend reinitiation of antifungal therapy with voriconazole, or another mold-active antifungal that the patient responded to and tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717720#H564717720\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Secondary prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link&amp;anchor=H20422993#H20422993\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\", section on 'Secondary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive aspergillosis is a major cause of death in immunosuppressed patients, particularly following hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/76\">",
"     76",
"    </a>",
"    ]. At one point, the one-year mortality rate after onset of invasive aspergillosis in this population was as high as 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/76\">",
"     76",
"    </a>",
"    ]. However, results of more recent studies demonstrate improved outcomes, both with regards to estimated attributable and overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2,62\">",
"     2,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a US-based multicenter surveillance study that enrolled patients from 2001 to 2005, the 12-week all-cause mortality among HCT recipients with invasive aspergillosis was 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/77\">",
"     77",
"    </a>",
"    ]. Lower mortality rates have been observed in trials that included patients other than HCT recipients. As an example, in one trial in which only 29 percent of patients were HCT recipients, the 12-week mortality in patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    was 29 versus 42 percent in those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Voriconazole'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies evaluating more homogeneous patient populations, such as those done only in HCT recipients, have shown a measurable increase in survival after the diagnosis of invasive aspergillosis in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2,78\">",
"     2,78",
"    </a>",
"    ]. However, variables that influence outcome include a complex combination of host factors, including the underlying disease, as well as the therapies used. Factors predictive of death include disseminated disease, cerebral involvement, persistent and severe neutropenia, administration of glucocorticoids, receipt of human leukocyte antigen-mismatched stem cells, and uncontrolled graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2,62,79,80\">",
"     2,62,79,80",
"    </a>",
"    ]. A delay in diagnosis may also lead to worse outcomes. As mentioned previously, multiple host factors, such as pulmonary function prior to transplant, and underlying organ (kidney and liver) function impact outcomes. There is some indication that recipients of non-myeloablative (or reduced intensity) conditioning regimens have relatively better outcomes after infection compared to patients who received myeloablative therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid use has been associated with higher mortality rates among HCT recipients in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/2,76-80\">",
"     2,76-80",
"    </a>",
"    ], but in one study of solid organ transplant recipients, glucocorticoid use resulted in a decreased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452339662\">",
"    <span class=\"h2\">",
"     Galactomannan assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum galactomannan assay may have prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/81-84\">",
"     81-84",
"    </a>",
"    ], as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 27 studies of patients with hematologic malignancies and proven or probable aspergillosis, patients with persistently positive galactomannan results were significantly more likely to die and to have autopsy-proven aspergillosis than those with a test that normalized in value [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study demonstrated that both the serum galactomannan value at the time of diagnosis of invasive aspergillosis and the one-week galactomannan decay were predictive of all-cause mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?28/18/28970/abstract/82\">",
"       82",
"      </a>",
"      ]. Each enzyme immunoassay (EIA) unit increase in galactomannan at the time of diagnosis increased the hazard of time to all-cause mortality at 6 weeks by 25 percent, whereas each galactomannan EIA unit decline during the week following the initial test decreased the risk of time to all-cause mortality at six weeks by 22 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486430#H1064486430\">",
"       \"Diagnosis of invasive aspergillosis\", section on 'Galactomannan antigen detection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/23/12658?source=see_link\">",
"       \"Patient information: Invasive aspergillosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspergillus species are ubiquitous, but invasive aspergillosis occurs primarily in immunocompromised hosts. Neutropenia and glucocorticoid use are the most common predisposing factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive aspergillosis is a major cause of death in immunosuppressed patients, particularly following hematopoietic cell transplantation (HCT). In a US-based multicenter study, the 12-week all-cause mortality among HCT recipients with invasive aspergillosis was 58 percent. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial therapy of patients with invasive aspergillosis, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      rather than a formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Echinocandins such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      may also be effective therapy, but have not been adequately studied. The recommended dosing regimen of voriconazole is 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV twice a day on day one followed by 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV twice daily. When the patient is able to take oral medications, one can consider switching voriconazole to 200 mg orally twice daily. (See",
"      <a class=\"local\" href=\"#H5048311\">",
"       'Choice of regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Voriconazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      for the treatment of invasive aspergillosis, particularly those receiving oral therapy, should undergo monitoring of serum voriconazole trough concentrations. Although there are no guidelines for target voriconazole concentrations, we suggest checking a trough concentration one week into therapy with a goal range of &gt;1",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and &lt;5.5",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Voriconazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , we suggest using a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (Abelcet or AmBisome) at 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Echinocandins are",
"      <strong>",
"       not",
"      </strong>",
"      recommended in this circumstance. (See",
"      <a class=\"local\" href=\"#H5048311\">",
"       'Choice of regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Lipid formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an invasive mold infection is suspected, and the likelihood of mucormycosis is increased due to recent receipt of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , we recommend treating empirically with a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      rather than voriconazole in order to provide antifungal activity against both aspergillosis and mucormycosis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). A definitive diagnosis should be pursued aggressively, and the regimen should be changed to voriconazole if the diagnosis of invasive aspergillosis is established. (See",
"      <a class=\"local\" href=\"#H5048311\">",
"       'Choice of regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, immunosuppression should be decreased as an adjunct to antifungal therapy for the treatment of invasive aspergillosis. (See",
"      <a class=\"local\" href=\"#H458851100\">",
"       'Immunomodulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical debridement is usually required for the treatment of Aspergillus rhinosinusitis, and may be indicated in settings in which antifungals cannot be delivered to large necrotic lesions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when there is an imminent threat to vessels. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Role of surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For salvage therapy in patients who do not respond to monotherapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      , we suggest the use of a combination antifungal regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Appropriate regimens include an echinocandin, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      , in combination with voriconazole or liposomal amphotericin",
"      <strong>",
"      </strong>",
"      B. There are no data to support the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      with a triazole for combination therapy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antifungal resistance should be considered in patients with A. fumigatus who do not respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , and in patients infected with certain Aspergillus species that have reduced antifungal susceptibility profiles (eg, A. terreus, A. ustus, A. lentulus, Neosartoria udagawae). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Voriconazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H458851271\">",
"       'Antifungal resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of therapy depends upon the location of the infection, the patient's underlying disease and need for further immunosuppression, and the response to therapy. For most immunosuppressed patients, antifungal therapy will continue for months or even years in some cases. (See",
"      <a class=\"local\" href=\"#H617627\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who complete antifungal therapy are at risk for relapse of aspergillosis during periods of increased immunosuppression, particularly if neutropenia recurs. We recommend reinitiation of antifungal therapy if chemotherapy is reinitiated and the patient is expected to become neutropenic or if immunosuppression is intensified (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H617627\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strategies to optimize management include prophylactic therapy and early treatment using empiric therapy of fever during periods of neutropenia. Another possible approach is preemptive therapy, which involves initiating antifungal therapy based upon the results of serial screening for aspergillosis. (See",
"      <a class=\"local\" href=\"#H833547\">",
"       'Prevention and early treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/1\">",
"      Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/2\">",
"      Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/3\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/4\">",
"      Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/5\">",
"      Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/6\">",
"      B&ouml;hme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl 2:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/7\">",
"      Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/8\">",
"      Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/9\">",
"      Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/10\">",
"      Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/11\">",
"      Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/12\">",
"      Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/13\">",
"      Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/14\">",
"      Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.",
"     </a>",
"    </li>",
"    <li>",
"     Vfend&reg; package insert. Roerig, a Division of Pfizer, Inc. New York, NY, 2008. file://media.pfizer.com/files/products/uspi_vfend.pdf (Accessed on November 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/16\">",
"      Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/17\">",
"      Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/18\">",
"      Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/19\">",
"      Howard SJ, Lestner JM, Sharp A, et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 2011; 203:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/20\">",
"      Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/21\">",
"      Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/22\">",
"      Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/23\">",
"      Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994; 97:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/24\">",
"      Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 Suppl 2:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/25\">",
"      Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/26\">",
"      Trullas JC, Cervera C, Benito N, et al. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. Transplant Proc 2005; 37:4091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/27\">",
"      McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/28\">",
"      Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/29\">",
"      Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/30\">",
"      Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/31\">",
"      Petraitiene R, Petraitis V, Lyman CA, et al. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2004; 48:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/32\">",
"      Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/33\">",
"      Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, et al. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 2006; 43:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/34\">",
"      Kauffman CA. New antifungal agents. Semin Respir Crit Care Med 2004; 25:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/35\">",
"      Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/36\">",
"      Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell 2006; 5:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/37\">",
"      Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/38\">",
"      Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5:e219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/39\">",
"      Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/40\">",
"      van der Linden JW, Jansen RR, Bresters D, et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009; 48:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/41\">",
"      Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/42\">",
"      Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/43\">",
"      Vazquez JA. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Clin Infect Dis 2008; 46:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/44\">",
"      Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs 2005; 65:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/45\">",
"      Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005; 56:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/46\">",
"      Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trials.gov. Anidulafungin plus voriconazole versus voriconazole for the treatment of invasive aspergillosis.",
" file://clinicaltrials.gov/ct2/show/NCT00531479?term=aspergillosis+AND+voriconazole+AND+anidulafungin&amp;rank=2 (Accessed on November 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/48\">",
"      Caillot D, Thi&eacute;baut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/49\">",
"      Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005; 103:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/50\">",
"      Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006; 194:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/51\">",
"      Sugar AM. Antifungal combination therapy: where we stand. Drug Resist Updat 1998; 1:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/52\">",
"      Sugar AM. Overview: antifungal combination therapy. Curr Opin Investig Drugs 2001; 2:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/53\">",
"      Perkhofer S, Lugger H, Dierich MP, Lass-Fl&ouml;rl C. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. Antimicrob Agents Chemother 2007; 51:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/54\">",
"      Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/55\">",
"      Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988; 85:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/56\">",
"      Salerno CT, Ouyang DW, Pederson TS, et al. Surgical therapy for pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 1998; 65:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/57\">",
"      Baron O, Guillaum&eacute; B, Moreau P, et al. Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases. J Thorac Cardiovasc Surg 1998; 115:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/58\">",
"      S&uuml;sl&uuml; AE, O��retmeno��lu O, S&uuml;sl&uuml; N, et al. Acute invasive fungal rhinosinusitis: our experience with 19 patients. Eur Arch Otorhinolaryngol 2009; 266:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/59\">",
"      Herbrecht R, Natarajan-Am&eacute; S, Letscher-Bru V, Canuet M. Invasive pulmonary aspergillosis. Semin Respir Crit Care Med 2004; 25:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/60\">",
"      Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004; 126:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/61\">",
"      Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/62\">",
"      Parody R, Martino R, S&aacute;nchez F, et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 2009; 84:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/63\">",
"      Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/64\">",
"      Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010; 50:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/65\">",
"      Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/66\">",
"      Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/67\">",
"      Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/68\">",
"      Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/69\">",
"      Winston DJ, Emmanouilides C, Bartoni K, et al. Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood 2004; 104:1581; author reply 1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/70\">",
"      Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/71\">",
"      Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/72\">",
"      Marr KA. Empirical antifungal therapy--new options, new tradeoffs. N Engl J Med 2002; 346:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/73\">",
"      Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/74\">",
"      Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/75\">",
"      Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/76\">",
"      Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/77\">",
"      Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/78\">",
"      Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/79\">",
"      Ribaud P, Chastang C, Latg&eacute; JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/80\">",
"      Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/81\">",
"      Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/82\">",
"      Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/83\">",
"      Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/18/28970/abstract/84\">",
"      Nou&eacute;r SA, Nucci M, Kumar NS, et al. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 2011; 53:671.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2459 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28970=[""].join("\n");
var outline_f28_18_28970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTIFUNGAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5048311\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34483456\">",
"      - Outbreak of fungal meningitis and septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Triazoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Amphotericin B deoxycholate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lipid formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Caspofungin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458851271\">",
"      Antifungal resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H617537\">",
"      - Voriconazole and caspofungin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Liposomal amphotericin B and caspofungin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Amphotericin B and triazoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H617627\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H834005\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458851100\">",
"      IMMUNOMODULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458851107\">",
"      Colony-stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458851114\">",
"      Granulocyte infusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ROLE OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H833547\">",
"      PREVENTION AND EARLY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H833572\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H833579\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H833586\">",
"      Preemptive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H833930\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452339662\">",
"      Galactomannan assay",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11178?source=related_link\">",
"      Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35270?source=related_link\">",
"      Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19321?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/23/12658?source=related_link\">",
"      Patient information: Invasive aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=related_link\">",
"      Pharmacology of echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=related_link\">",
"      Treatment of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=related_link\">",
"      Voriconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_18_28971="Complement fragment functions";
var content_f28_18_28971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activated complement fragments: Deposition and function on cellular targets",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Activation fragment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number on a single cell",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C4b",
"       </td>",
"       <td>",
"        2.5 million",
"       </td>",
"       <td>",
"        Cleavage by C1s generates C4b; C4b covalently binds to target",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C4bC2a",
"       </td>",
"       <td>",
"        0.5 million",
"       </td>",
"       <td>",
"        C3 convertase; one in five C4bs forms a convertase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C3b",
"       </td>",
"       <td>",
"        20 million",
"       </td>",
"       <td>",
"        ~10x more C3b than C4b attaches to target (opsonization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C5b-C9",
"       </td>",
"       <td>",
"        1 million",
"       </td>",
"       <td>",
"        Membrane perturbation including lysis by the membrane attack complex",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These data were obtained from quantitative analysis of IgG antibody-mediated classical pathway activation on mammalian cells (melanoma cell line). Normal human serum was used as the source of complement, along with saturating amounts of human antibody to the cell line. Similar data have been obtained on bacterial membranes, although relative numbers were less (approximately a log) corresponding to reduced surface area and antigenic density. The complement system is the \"guardian of the intravascular space.\" It is designed to attack bacteria attempting to enter the intravascular space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28971=[""].join("\n");
var outline_f28_18_28971=null;
var title_f28_18_28972="Causes diaphragmatic paralysis";
var content_f28_18_28972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of diaphragmatic paralysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinal cord transection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyotrophic lateral sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cervical spondylosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Poliomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Guillain-Barre syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Phrenic nerve dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Compression by tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cardiac surgery cold injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Blunt trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Idiopathic phrenic neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Postviral phrenic neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Radiation therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cervical chiropractic manipulation",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Myopathic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Limb-girdle dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperthyroidism or hypothyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malnutrition",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acid maltase deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Connective tissue diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Systemic lupus erythematosus&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Dermatomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mixed connective tissue disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyloidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic myopathy",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28972=[""].join("\n");
var outline_f28_18_28972=null;
var title_f28_18_28973="Differential splicing mRNA";
var content_f28_18_28973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F70768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F70768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Differential splicing of mRNAs encoding membrane and secreted forms of IgM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The carboxyl terminus of secreted IgM (&micro;s) is encoded by the C&micro;4 exon. The carboxyl terminus of membrane IgM (&micro;m) is encoded by a separate exon a short distance 3' to C&micro;4. Differential splicing of the same primary transcript generates mRNA encoding either &micro;s or &micro;m.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bona, C, Bonilla, FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright &copy; 1996 Overseas Publishers Association, N.V. Permission granted by Gordon and Breach Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28973=[""].join("\n");
var outline_f28_18_28973=null;
var title_f28_18_28974="Concentration and dilution";
var content_f28_18_28974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Summary of NaCl and H20 transport throughout the nephron during an antidiuresis and a water diuresis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tubular fluid and interstitial concentrations are expressed in milliosmoles per kilogram (mosmol/kg;) the large, boxed numbers represent the percentage of the glomerular filtrate remaining in the tubule at each site. Note that the composition and volume of the tubular fluid are essentially the same at the end of the loop of Henle as the excretion of a concentrated or dilute urine is determined primarily in the collecting tubules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28974=[""].join("\n");
var outline_f28_18_28974=null;
var title_f28_18_28975="Mobilization of the cervical esophagus";
var content_f28_18_28975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Mobilization of the cervical esophagus and creation of an esophagostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the mobilization of the distal esophagus in preparation for a cervical esophagostomy. The proximal length should be preserved in order to facilitate placement of the esophagostomy on the anterior chest wall. The recurrent laryngeal nerve, which lies in the tracheo-esophageal groove, should be protected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_18_28975=[""].join("\n");
var outline_f28_18_28975=null;
